Xtant Medical (XTNT) 10-K 18 Mar 15 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 10, 2015	Jun. 30, 2014
Document Information [Line Items]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Entity Registrant Name	Bacterin International Holdings, Inc.
Entity Central Index Key	1453593
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$31,947,107
Trading Symbol	BONE
Entity Common Stock, Shares Outstanding		6,683,056

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current Assets:
Cash and cash equivalents	$4,468,208	$3,046,340
Trade accounts receivable, net of allowance for doubtful accounts of $1,392,989 and $1,309,859, respectively	4,427,081	4,793,834
Inventories, net	9,558,648	10,753,600
Prepaid and other current assets	654,140	574,910
Total current assets	19,108,077	19,168,684
Non-current inventories	1,934,258	2,119,952
Property and equipment, net	4,654,527	5,180,556
Intangible assets, net	655,490	586,965
Other assets	1,598,539	1,821,471
Total Assets	27,950,891	28,877,628
Current Liabilities:
Accounts payable	3,876,760	2,767,639
Accounts payable - related party	250,629	647,844
Accrued liabilities	1,921,301	3,585,037
Warrant derivative liability	1,320,371	1,594,628
Current portion of capital lease obligations	61,970	171,926
Current portion of royalty liability	1,000,750	836,750
Current portion of long-term debt	50,671	47,727
Total current liabilities	8,482,452	9,651,551
Long-term Liabilities:
Capital lease obligation, less current portion	11,808	73,777
Long-term royalty liability, less current portion	6,361,216	6,609,232
Long-term debt, less current portion	20,870,330	16,385,245
Total Liabilities	35,725,806	32,719,805
Commitments and Contingencies
Stockholders' (Deficit) Equity
Preferred stock, $0.000001 par value; 5,000,000 shares authorized; no shares issued and Outstanding	0	0
Common stock, $0.000001 par value; 95,000,000 shares authorized; 6,679,646 shares issued and outstanding as of December 31, 2014 and 5,343,282 shares issued and outstanding as of December 31, 2013	7	5
Additional paid-in capital	63,091,620	56,516,491
Accumulated deficit	-70,866,542	-60,358,673
Total Stockholders’ Deficit	-7,774,915	-3,842,177
Total Liabilities & Stockholders’ Deficit	$27,950,891	$28,877,628

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)	Dec. 31, 2014	Dec. 31, 2013
Trade accounts receivable, allowance for doubtful accounts (in dollars)	$1,392,989	$1,309,859
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	95,000,000	95,000,000
Common stock, shares issued	6,679,646	5,343,282
Common Stock, shares outstanding	6,679,646	5,343,282

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Revenue
Tissue sales	$34,569,160	$32,563,933
Royalties and other	762,652	509,481
Total Revenue	35,331,812	33,073,414
Cost of sales	13,034,314	14,185,719
Gross Profit	22,297,498	18,887,695
Operating Expenses
General and administrative	8,886,972	10,204,659
Sales and marketing	16,912,865	16,017,229
Research and development	1,443,018	572,361
Depreciation and amortization	271,748	377,524
Impairment of assets	912,549	728,618
Non-cash consulting expense	135,075	-5,117
Total Operating Expenses	28,562,227	27,895,274
Loss from Operations	-6,264,729	-9,007,579
Other Income (Expense)
Interest expense	-5,660,357	-4,653,232
Change in warrant derivative liability	1,736,053	875,041
Other (expense)	-318,836	92,645
Total Other Income (Expense)	-4,243,140	-3,685,546
Net Loss from Operations Before (Provision) Benefit for Income Taxes	-10,507,869	-12,693,125
(Provision) Benefit for Income Taxes
Current	0	0
Deferred	0	0
Net Loss	($10,507,869)	($12,693,125)
Net loss per share:
Basic (in dollars per share)	($1.76)	($2.80)
Dilutive (in dollars per share)	($1.76)	($2.80)
Shares used in the computation:
Basic (in shares)	5,954,195	4,530,072
Dilutive (in shares)	5,954,195	4,530,072

Consolidated_Statements_of_Cha

Consolidated Statements of Changes in Stockholders' Equity (Deficit) (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]
Balance at Dec. 31, 2012	$4,232,385	$3	$51,897,930	($47,665,548)
Balance (in shares) at Dec. 31, 2012		4,287,777
Stock-based compensation	996,307	0	996,307	0
Stock-based compensation (in shares)		31,628
Exercise of options	27,575	0	27,575	0
Exercise of options (in shares)		23,000
Net proceeds from the issuance of stock	4,449,994	1	4,449,993
Net proceeds from the issuance of stock (in shares)		850,877
Issuance of warrants in conjunction with the issuance of stock	-1,485,313	0	-1,485,313	0
Issuance of stock to ROS in exchange for debt waiver	630,000	1	629,999	0
Issuance of stock to ROS in exchange for debt waiver (in shares)		150,000
Net loss	-12,693,125	0	0	-12,693,125
Balance at Dec. 31, 2013	-3,842,177	5	56,516,491	-60,358,673
Balance (in shares) at Dec. 31, 2013		5,348,282
Stock-based compensation	935,316	0	935,316	0
Stock-based compensation (in shares)		38,364
Net proceeds from the issuance of stock	5,869,635	2	5,869,633	0
Net proceeds from the issuance of stock (in shares)		1,143,000
Issuance of restricted stock to employees	136,977	0	136,977	0
Issuance of warrants in conjunction with the issuance of stock	-1,461,796	0	-1,461,796	0
Issuance of stock to ROS in exchange for debt waiver	1,094,999	0	1,094,999	0
Issuance of stock to ROS in exchange for debt waiver (in shares)		150,000
Net loss	-10,507,869	0	0	-10,507,869
Balance at Dec. 31, 2014	($7,774,915)	$7	$63,091,620	($70,866,542)
Balance (in shares) at Dec. 31, 2014		6,679,646

Consolidated_Statements_of_Cha1

Consolidated Statements of Changes in Stockholders' Equity (Deficit) [Parenthetical] (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014
Proceeds from Lines of Credit	$4

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Operating activities:
Net loss	($10,507,869)	($12,693,125)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	952,320	753,522
Non-cash interest	814,374	633,398
Impairment of Assets	912,549	728,618
Loss (Gain) on sale of fixed assets	25,269	-500
Amortization of debt discount	1,632,245	1,251,125
Non-cash consulting expense/stock option expense	935,316	838,847
Provision for losses on accounts receivable and inventory	647,765	2,320,955
Gain in derivative warrant liability	-1,736,053	-875,041
Decrease of contingent liability	0	-91,740
Changes in operating assets and liabilities:
Accounts receivable	283,624	797,680
Inventories	-17,392	747,691
Prepaid and other assets	-455,048	263,352
Accounts payable	715,706	-1,001,228
Accrued liabilities	-1,526,865	1,434,140
Net cash used in operating activities	-7,324,059	-4,892,306
Investing activities:
Purchases of property and equipment and intangible assets	-299,978	-623,045
Proceeds from sale of fixed assets	1,626	-70,255
Net cash used in investing activities	-298,352	-693,300
Financing activities:
Proceeds from issuance of debt	4,000,000	0
Payments on long-term debt	-653,397	-621,967
Payments on capital leases	-171,957	-149,729
Proceeds from exercise of options	0	27,575
Net proceeds from issuance of stock	5,869,633	4,450,001
Net cash provided by financing activities	9,044,279	3,705,880
Net change in cash and cash equivalents	1,421,868	-1,879,726
Cash and cash equivalents at beginning of period	3,046,340	4,926,066
Cash and cash equivalents at end of period	$4,468,208	$3,046,340

Business_Description_and_Summa

Business Description and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Description and Summary of Significant Accounting Policies	(1)     Business Description and Summary of Significant Accounting Policies
	Business Description
	The accompanying consolidated financial statements include the accounts of Bacterin International Holdings, Inc., a Delaware corporation, and its wholly owned subsidiary, Bacterin International, Inc., a Nevada corporation, (collectively, the “Company” or “Bacterin”). All intercompany balances and transactions have been eliminated in consolidation. Bacterin develops, manufactures and markets biologics products to domestic and international markets.  Bacterin’s proprietary methods are used in human allografts to create scaffolds and promote bone and other tissue growth.  These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain with a facet joint stabilization, promotion of bone growth in foot and ankle surgery, promotion of skull healing following neurosurgery and regeneration in knee and other joint surgeries.
	Bacterin also develops and licenses coatings for various medical device applications.  As of December 31, 2014, Bacterin made a strategic decision to discontinue the medical device coatings business which resulted in an impairment of related assets. See Note 4, “Impairment of Assets”.
	An operating segment is a component of an enterprise whose operating results are regularly reviewed by the enterprise’s chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance. The primary performance measure used by management is net income or loss. Up until December 31, 2014, the Company operated two distinct lines of business consisting of the biologics and the device divisions. With the strategic exit from the devices business as of December 31, 2014, the Company will be operating as a single business segment in 2015.
	The Company's revenue is derived principally from the sale of its biologics products. The markets in which the Company competes are highly competitive and rapidly changing. Significant technological advances, changes in customer requirements, or the emergence of competitive products with new capabilities or technologies could adversely affect the Company's operating results. The Company's business could be harmed by a decline in demand for, or in the prices of, its products or as a result of, among other factors, any change in pricing or distribution model, increased price competition, changes in government regulations or a failure by the Company to keep up with technological change.  Further, a decline in available tissue donors could have an adverse impact on our business.
	Reverse Stock Split
	The Company completed a 1:10 reverse split of its common stock, effective at the close of business on Friday, July 25, 2014 and in effect for trading purposes on Monday, July 28, 2014. The reverse stock split was approved by the Company's shareholders at the 2014 Annual Meeting of Shareholders on June 11, 2014.  All references to common shares, stock option, restricted stock units, warrants, and per share amounts have been retroactively adjusted to reflect the reverse stock split for all periods presented.
	Public Offering
	In August 2014, the Company offered 1,143,000 shares of its common stock at $5.70 per share and warrants to purchase 571,500 shares of its common stock at an exercise price of $7.12 per share to the public.  Gross proceeds of the offering were approximately $6.5 million. Net proceeds from the offering were approximately $5.9 million and will be used for working capital and general corporate purposes, including the continued expansion of the company's sales force and increasing inventory levels to support anticipated future growth.  The offering closed on August 6, 2014.
	The warrants have a five year term and expire on August 6, 2019.  The Company utilizes a lattice model to determine the fair market value and accounts for these warrants as a derivative liability (see "Derivative Instruments" below).  Also, see Note 10, "Warrants"  below.
	Concentrations and Credit Risk
	The Company’s accounts receivable are due from a variety of health care organizations and distributors throughout the world. Approximately 98% of sales were in the United States for 2014 and 2013.  No single customer accounted for more than 10% of revenue or accounts receivable for 2014 and 2013.  The Company provides for uncollectible amounts when specific credit issues arise. Management’s estimates for uncollectible amounts have been adequate during prior periods, and management believes that all significant credit risks have been identified at December 31, 2014.
	Revenue by geographical region is as follows:
		Year ended
		December 31,
		2014		2013
	United States	$	34,643,571	$	32,458,822
	Rest of World		688,241		584,592
		$	35,331,812	$	33,073,414
	Use of Estimates
	The preparation of the financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Significant estimates include the carrying amount of property and equipment and intangible assets; valuation allowances for trade receivables and deferred income tax assets; valuation of the warrant derivative liability; inventory reserve; royalty liability; and estimates for the fair value of stock options grants and other equity awards upon which the Company determines stock-based compensation expense. Actual results could differ from those estimates.
	Reclassifications
	Certain comparative balances for year ended December 31, 2013 have been reclassified to make them consistent with the current year presentation. The reclassifications had no effect on the net income for 2013.
	Cash and Cash Equivalents
	The Company considers all highly liquid investments purchased with an original maturity date of three months or less to be cash equivalents.  Cash equivalents are recorded at cost, which approximates market value. At times the Company maintains deposits in financial institutions in excess of federally insured limits.
	Accounts Receivable
	Accounts receivable represents amounts due from customers for which revenue has been recognized. Normal terms on trade accounts receivable are net 30 days and some customers are offered discounts for early pay.   The Company performs credit evaluations when considered necessary, but generally does not require collateral to extend credit.
	The allowance for doubtful accounts is the Company's best estimate of the amount of probable credit losses in the Company's existing receivables. The Company determines the allowance based on factors such as historical collection experience, customer's current creditworthiness, customer concentration, age of accounts receivable balance, general economic conditions that may affect a customer's ability to pay and management judgment. Actual customer collections could differ from estimates. Account balances are charged to the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Provisions to the allowance for doubtful accounts are charged to expense. The Company does not have any off-balance sheet credit exposure related to its customers.
	Inventories
	Inventories are stated at the lower of cost or market.  Cost is determined using the specific identification method and includes materials, labor and overhead. The Company calculates an inventory reserve for estimated obsolescence or excess inventory based on historical usage and sales, as well as assumptions about future demand for its products. These estimates for excess and obsolete inventory are reviewed and updated on a quarterly basis. Increases in the inventory reserves result in a corresponding expense, which is recorded to cost of tissue and medical devices sales. Inventories where the sales cycle is estimated to be beyond twelve months are classified as Non-current inventories.
	Property and Equipment
	Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to seven years for computers and equipment, and 30 years for buildings. Leasehold improvements are depreciated over the shorter of their estimated useful life or the remaining term of the lease. Repairs and maintenance are expensed as incurred.
	Goodwill
	Goodwill represents the excess of costs over fair value of assets of businesses acquired. Goodwill and intangible assets acquired in a purchase business combination and determined to have indefinite useful lives are not amortized, instead are tested for impairment at least annually and whenever events or circumstances indicate the carrying amount of the asset may not be recoverable. The Company conducts its annual impairment test on December 31 of each year. In its evaluation of goodwill in 2013, the Company performed an assessment of qualitative factors to determine if it is more-likely-than-not that goodwill might be impaired and whether it is necessary to perform the two-step goodwill impairment. See Note 4, “Impairment of Assets”.
	Derivative Instruments
	The Company accounts for its derivative instruments in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 815 “Accounting for Derivative Instruments and Hedging Activities”. The only derivative instruments presented in the accompanying consolidated financial statements relate to warrants issued in connection with certain debt and equity financings. The Company has not designated its warrant derivative liability as a hedging instrument as described in ASC 815 and any change in the fair market value of the warrant derivative liability is recognized in the consolidated statement of operations during the period of change. See Note 10, “Warrants” below.
	Intangible Assets
	Intangible assets with estimable useful lives must be amortized over their respective estimated useful lives to their estimated residual values, and reviewed for impairment whenever events or circumstances indicate their carrying amount may not be recoverable. Intangible assets include trademarks and patents and include costs to acquire and protect Company patents. Intangible assets are carried at cost less accumulated amortization. The Company amortizes these assets on a straight-line basis over their estimated useful lives of fifteen years.
	Other Assets
	Other Assets consist of the short-term and the long-term portion of prepaid expenses, security deposits, the capitalized portion of debt related issuance costs and kits that are used in the implantation of certain biologic products. The items are stated at cost and in the case of debt related issuance costs and kits are amortized on a straight line basis over their estimated useful lives.
	Accounts Payable - Related Party
	Accounts payable to a related party includes amounts due to American Donor Services and West Coast Tissue Services, as suppliers of donors to the Company for 2014 and 2013. See Note 15, “Related Party Transactions” below.
	Revenue Recognition
	Revenue is recognized when all of the following criteria are met: a) the Company has entered into a legally binding agreement with the customer; b) the products or services have been delivered; c) the Company's fee for providing the products and services is fixed or determinable; and d) collection of the Company’s fee is probable.
	The Company’s policy is to record revenue net of any applicable sales, use, or excise taxes.  If an arrangement includes a right of acceptance or a right to cancel, revenue is recognized when acceptance is received or the right to cancel has expired.
	The Company ships to certain customers under consignment arrangements whereby the Company’s product is stored by the customer.  The customer is required to report the use to the Company and upon such notice, the Company invoices the customer and revenue is recognized when above criteria have been met.
	The Company also receives royalty revenue from third parties related to licensing agreements. The Company has royalty agreements with RyMed and Bard Access Systems. Revenue under these agreements represented less than 0.5% of total revenue for the years ended December 31, 2014 and 2013.
	Non-Cash Consulting Expense
	From time to time, the Company issues restricted stock awards to consultants and advisors to the Company. These awards are measured at fair value at each reporting date, recognized ratably over the vesting period and are recorded in non-cash consulting expense.
	Advertising Costs
	The Company expenses advertising costs as incurred. The Company had advertising expense of $34,970 and $47,000 for the years ended December 31, 2014 and 2013, respectively.
	Research and Development
	Research and development costs, which are principally related to internal costs for the development of new technologies and processes for tissue and coatings, are expensed as incurred.
	Income Taxes
	The Company accounts for income taxes under the asset and liability method of accounting for deferred taxes as prescribed under FASB ASC 740, "Accounting for Income Taxes".  Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. When applicable, a valuation allowance is established to reduce any deferred tax asset when it is determined that it is more likely than not that some portion of the deferred tax asset will not be realized. ASC 740 also requires reporting of taxes based on tax positions that meet a more-likely-than-not standard and that are measured at the amount that is more-likely-than-not to be realized. Differences between financial and tax reporting which do not meet this threshold are required to be recorded as unrecognized tax benefits. ASC 740 also provides guidance on the presentation of tax matters and the recognition of potential IRS interest and penalties. The Company classifies penalty and interest expense related to income tax liabilities as an income tax expense. There are no significant interest and penalties recognized in the statement of operations or accrued on the balance sheet. See Note 12, “Income Taxes” below.
	Long-Lived Assets
	Long-lived assets, including intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. See Note 4, “Impairment of Assets”.
	Net Loss Per Share
	Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding. Shares issued during the period and shares reacquired during the period are weighted for the portion of the period that they were outstanding. Diluted net income (loss) per share is computed in a manner consistent with that of basic earnings per share while giving effect to all potentially dilutive common shares outstanding during the period, which include the assumed exercise of stock options and warrants using the treasury stock method.  Diluted net loss per share was the same as basic net loss per share for the years ended December 31, 2014 and 2013, as shares issuable upon the exercise of stock options and warrants were anti-dilutive as a result of the net losses incurred for those periods.  Dilutive earnings per share are not reported as their effects of including 2,350,656 and 1,846,148 outstanding stock options and warrants for the years ended December 31, 2014 and 2013, respectively, are anti-dilutive.
	Stock-Based Compensation
	The Company records stock-compensation expense according to the provisions of FASB ASC 718 “Compensation – Stock Compensation”.  Under ASC 718, stock-based compensation costs are recognized based on the estimated fair value at the grant date for all stock-based awards.  The Company estimates grant date fair values using the Black-Scholes-Merton option pricing model, which requires assumptions of the life of the award and the stock price volatility over the term of the award.  The Company records Compensation cost of stock-based awards using the straight line method, which is recorded into earnings over the vesting period of the award.
	Fair Value of Financial Instruments
	The carrying values of financial instruments, including trade accounts receivable, accounts payable, other accrued expenses and long-term debt, approximate their fair values based on terms and related interest rates.
The Company follows a framework for measuring fair value. The framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:
Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets.
Level 2: Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.
A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. During the years ended December 31, 2014 and 2013, there was no reclassification in financial assets or liabilities between Level 1, 2 or 3 categories.
The following tables set forth by level, within the fair value hierarchy, our assets and liabilities as of the years ended December 31, 2014 and December 31, 2013, respectively, that are measured at fair value on a recurring basis:
Accrued stock compensation
	As of		As of
	December 31,		December 31,
	2014		2013
Level 1	$	-	$	211,212
Level 2		-		-
Level 3		-		-
The valuation technique used to measure fair value of the accrued stock compensation is based on quoted stock market prices.
Warrant derivative liability
	As of		As of
	December 31,		December 31,
	2014		2013
Level 1		-		-
Level 2		-		-
Level 3	$	1,320,371	$	1,594,628
The valuation technique used to measure fair value of the warrant liability is based on a lattice model and significant assumptions and inputs determined by us.
Level 3 Changes
The following is a reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the year ending December 31, 2014:
Warrant derivative liability
Balance at January 1, 2014	$	1,594,628
Warrants issued with stock offering		1,461,796
Gain recognized in earnings		-1,736,053
Balance at December 31, 2014	$	1,320,371
During the year ended December 31, 2014, the Company did not change any of the valuation techniques used to measure its liabilities at fair value.
Recent Accounting Pronouncements
In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 supersedes the revenue recognition guidance in Topic 605, Revenue Recognition. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods and services to customers in an amount that reflects the consideration to which the entity expects to be entitled in the exchange for those goods or services. This standard is effective for annual reporting periods beginning after December 15, 2016. ASU 2014-09 is not expected to have a material impact on our consolidated financial position, results of operations, or cash flows.
In August 2014, FASB issued ASU No. 2014-15, Preparation of Financial Statements - Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern.  Under GAAP, continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity's liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting.  If and when an entity's liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements-Liquidation Basis of Accounting.  Even when an entity's liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity's ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events.  The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter.  Early application is permitted. The Company will evaluate the going concern considerations in this ASU, but has not elected early application.
In November 2014, FASB issued ASU No. 2014-08, Presentation of Financial Statements (Topic 201) and Property, Plant and Equipment (Topic 360) - Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. The amendments in this Update are effective for the annual period ending after December 15, 2014, and interim periods within those years. Early adoption is permitted only for disposals (or classifications as held for sale) that have not been reported in financial statements previously issued or available for issuance. ASU 2014-08 is not expected to have a material impact on our consolidated financial position, results of operations, or cash flows.

Equity

Equity	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Equity	(2)   Equity
	On June 10, 2013, the Company issued approximately 851,000 shares of common stock to new and existing investors at a price per share of $5.70, which represented a 10% discount to the closing price on June 4, 2013. For each common share purchased in the offering, investors received a warrant providing the right to purchase 0.5 shares of Bacterin common stock at an exercise price of $7.20, a 15% premium to the June 4, 2013 closing price. The warrants will be exercisable for seven years beginning 6 months from the date of issuance. The transaction resulted in net proceeds to the Company of approximately $4.45 million, after deducting approximately $400,000 for placement agent’s fees and offering expenses. Proceeds from the transaction were used to fund the Company's operations and working capital requirements.
	On November 14, 2013, the Company received a waiver from ROS Acquisition Offshore LP (“ROS”) for failure to achieve $10.5 million of revenue in the third quarter of 2013. In exchange for the waiver and reduction of future quarterly minimum revenue thresholds, the Company issued 150,000 shares of restricted stock to an affiliate of ROS on November 25, 2013.
	During the first quarter of 2014, the Company issued 150,000 shares of common stock to an affiliate of ROS pursuant to a Sixth Amendment to our Credit Agreement with ROS whereby we borrowed an additional $4 million under our Credit Agreement.  This issuance has been accounted for as a debt discount and will be amortized over the life of the loan.  See Note 8, “Long-Term Debt” below.
	In August 2014, the Company offered 1,143,000 shares of its common stock at $5.70 per share and warrants to purchase 571,500 shares of its common stock at an exercise price of $7.12 per share to the public.  Gross proceeds of the offering were approximately $6.5 million. Net proceeds from the offering were approximately $5.9 million and are expected to be used for working capital and general corporate purposes including the continued expansion of the company's sales force and increasing inventory levels to support anticipated future growth.  The offering closed on August 6, 2014.
	The warrants have a five year term and expire on August 6, 2019.  The Company utilizes a valuation model to determine the fair market value and accounts for these warrants as a derivative liability (See Note 1, Derivative Instruments" above). Also, see Note 10, "Warrants" below.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventories	(3)   Inventories
	Inventories consist of the following:
		December 31,		December 31,
		2014		2013
	Current inventories
	Raw materials	$	3,836,635	$	2,710,091
	Work in process		2,484,635		3,333,672
	Finished goods		5,163,458		5,775,813
			11,484,728		11,819,576
	Reserve for obsolescence		-1,926,080		-1,065,976
	Current inventories, total		9,558,648		10,753,600
	Non-current inventories
	Finished goods		2,860,248		3,341,411
	Reserve for obsolescence		-925,990		-1,221,459
	Non-current inventories, total		1,934,258		2,119,952
	Total inventories	$	11,492,906	$	12,873,552

Impairment_of_Assets

Impairment of Assets	12 Months Ended
	Dec. 31, 2014
Impairment or Disposal of Tangible Assets Disclosure [Abstract]
Impairment of Assets	(4)   Impairment of Assets
	In 2013, after reviewing the full year product line sales associated with the goodwill asset and the fact that the sales were not meeting original projections, management engaged an independent third party to review the asset for impairment in accordance with and pursuant to ASC 350 and ASC 360-10. The implied fair value of the goodwill was determined in the same manner as the amount of goodwill recognized in a business combination, as determined under ASC 805. In 2013, the management concluded that the goodwill asset was in fact impaired and should be written down fully to $0 indicating a goodwill impairment amount of $728,618.
	During the fourth quarter of 2014, management decided to dispose of a group of components because of a shift in strategy for the Company. The component groups are the inventory and fixed assets associated with the Device Coatings and Cranial Maxillofacial Fixation (CMF) lines of business.
	Sales for these product lines represented 1.2% of total revenue in 2013 and 1.4% of total revenue in 2014. Gross profit associated with these product lines were less than 1% of total gross profit for both the years 2013 and 2014.
	Management has committed to a plan to sell the component assets and the assets are available for immediate sale in their present condition. As of February 2015, management has identified a potential buyer for the device coatings product line and has entered into an agreement with another party for the inventory of the CMF product line.
	Total assets associated with the two lines includes $80,042 of related fixed assets, net of depreciation, and related inventory of $832,507 for a total value of $912,549. These assets were transferred to Assets held for Sale and are classified on the balance sheet as part of “Prepaid and other current assets”. After the impairment provision, the net balance of the Assets held for Sale is $0.
	Because the device coatings agreement is in the early stage of negotiations and the sale of the CMF inventory did not result in any tangible compensation, management has decided to reserve for the entire amount and has recorded a loss from impairment of assets of $912,549 on the 2014 Consolidated Statement of Operations.

Property_and_Equipment_Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	(5)   Property and Equipment, Net
	Property and equipment, net are as follows:
		December 31,		December 31,
		2014		2013
	Buildings	$	1,657,579	$	1,653,263
	Equipment		4,724,608		5,768,478
	Computer equipment		225,009		312,650
	Computer software		345,039		395,146
	Furniture and fixtures		153,834		170,118
	Leasehold improvements		2,380,617		1,808,461
	Vehicles		41,099		41,099
	Total cost		9,527,785		10,149,215
	Less: accumulated depreciation		-4,873,258		-4,968,659
		$	4,654,527	$	5,180,556
	The Company leases certain equipment under capital leases. For financial reporting purposes, minimum lease payments relating to the assets have been capitalized. As of December 31, 2014, the Company has recorded $443,060 gross assets in Equipment, and $191,174 of accumulated depreciation relating to assets under capital leases. As of December 31, 2013, the Company had recorded $549,604 gross assets in Equipment, and $159,722 of accumulated depreciation relating to assets under capital leases.
	Maintenance and repairs expense for the years ended 2014 and 2013 was $293,707 and $244,398, respectively.  Depreciation expense related to property and equipment, including property under capital lease for the years ended 2014 and 2013 was $570,726 and $677,856, respectively.

Intangible_Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	(6)   Intangible Assets
	Bacterin has applied for various patents with regards to processes for its products.
	The following table sets forth information regarding intangible assets:
		December 31,		December 31,
		2014		2013
	Intellectual Property
	Gross carrying value	$	1,036,580	$	891,034
	Accumulated amortization		-381,090		-304,069
	Net carrying value	$	655,490	$	586,965
	Aggregate amortization expense for the years ended December 31, 2014 and 2013, respectively:	$	77,022	$	75,668
	The following is a summary of estimated future amortization expense for intangible assets as of December 31, 2014:
	2015	$	90,055
	2016		58,639
	2017		58,639
	2018		58,639
	2019		55,105
	Thereafter		334,413
	Total	$	655,490

Accrued_Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Accrued Liabilities	(7)   Accrued Liabilities
	Accrued liabilities consist of the following:
		December 31,		December 31,
		2014		2013
	Accrued stock compensation	$	-	$	211,212
	Wages/commissions payable		1,434,743		1,728,576
	Other accrued expenses		486,558		1,645,249
		$	1,921,301	$	3,585,037

Longterm_Debt

Long-term Debt	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Long-term Debt	(8)   Long-term Debt
	On August 24, 2012, the Company entered into a Credit Agreement with ROS, which provided for an initial $20 million term loan.  The Credit Agreement also provided for an additional $5 million upon achievement prior to December 31, 2013 of certain revenue objectives, which were not achieved. The Company received net proceeds from ROS of approximately $10 million following repayment of the existing term loan and accounts receivable credit facility with MidCap Financial, including prepayment penalties. The Company used the net proceeds for working capital and general corporate purposes. The loan carries an interest rate of LIBOR plus 12.13%, subject to a LIBOR floor rate of 1.0%. Bacterin also agreed to pay a royalty of 1.75% on the first $45,000,000 of net sales, plus 1.0% of net sales in excess of $45,000,000 for ten years. Upon the occurrence of a defined event of default, ROS has the option to require the Company to purchase from ROS all of its rights to the remaining royalty payments that will become due in accordance with the royalty agreement (the “ROS Put Option”).  The ROS Put Option meets the definition of an embedded derivative and we concluded it had an immaterial value at December 31, 2014 and 2013. As such, the Company has not recorded a derivative liability related to the ROS Put Option and has not recognized any change in the fair value of this derivative liability in the consolidated financial statements because the impact is immaterial.  Management will reassess the fair value of the embedded derivative instrument at each reporting period and record if and when it becomes material to the consolidated financial statements.
	Bacterin has the right to repurchase the loan and royalty interest at amounts to be determined based on the date of repurchase, less the amount of prior principal, interest and royalty payments.  We will also have to pay fees, currently in the amount of 3.5% of the aggregate principal amount of the loan, as a result of waivers and modifications we have received in connection with the financial covenants in the Credit Agreement. The loan is secured by substantially all of our assets. The estimate of the royalty component of the facility over the life of the agreement resulted in a debt discount and a royalty liability of $7,361,966. The debt discount will be amortized to interest expense over the seven year term of the loan using the effective interest method. The royalty liability will be accreted to $12.3 million through interest expense over the ten year term of the royalty agreement using the effective interest method.
	The repurchase price, per the table below, following the additional $4 million we borrowed on March 6, 2014 and before deducting the amount of prior principal, interest and royalty payments, is as follows: (a) $40,000,000 if we exercise the repurchase option between August 24, 2014 and August 24, 2015; (b) $45,000,000 if we exercise the purchase option between August 24, 2015 and August 24, 2016; (c) $52,500,000 if we exercise the repurchase option between August 24, 2016 and August 24, 2017; and (d) $56,250,000 if we exercise the repurchase option after August 24, 2017. The following table provides an approximation of the repurchase price based on revenue equal to the minimum revenue required pursuant to the financial covenants in our Credit Agreement and four years of interest only payments with principal and interest amortized over years five through seven. Any modification in the payment schedule or in actual revenue achieved would change the Net Buyout Amount in the table below. The estimated amounts in the table below do not include fees payable on the aggregate principal amount of the loan pursuant to waivers and modifications to the Credit Agreement. The table below is for illustration purposes only and there can be no assurance that we will achieve the minimum revenue required by the financial covenants or that we will make all required payments on a timely basis.
	Calculation of ROS Buyout	Repurchase		Interest/		Estimated		Estimated		Net
		Price		Principal		Royalty on		Total		Buyout
				Payments		Minimum		Cumulative		Amount
						revenue		Payments
	Between August 24, 2014 and August 24, 2015	$	40,000,000	$	3,151,200	$	638,750	$	10,508,117	$	29,491,883
	Between August 24, 2015 and August 24, 2016	$	45,000,000	$	3,151,200	$	665,000	$	14,324,317	$	30,675,683
	Between August 24, 2016 and August 24, 2017	$	52,500,000	$	9,721,896	$	665,000	$	24,711,213	$	27,788,787
	After August 24, 2017	$	56,250,000	$	9,721,896	$	665,000	$	35,098,109	$	21,151,891
	In 2013, we entered into a number of waivers and amendments to our credit facility with ROS, including amendments that increased the amount payable to ROS.  These waivers and amendments are summarized below.
	On May 16, 2013, we entered into an amendment to our Credit Agreement with ROS, whereby ROS agreed to reduce our minimum liquidity requirement from $1,500,000 to $750,000 until September 30, 2013. In exchange, we agreed to pay a fee in the amount of 1.5% of the aggregate amount of any principal payment, prepayment or repayment.
	On August 12, 2013, we entered into a Waiver and Second Amendment to our Credit Agreement with ROS whereby we granted ROS Board observer rights in exchange for a waiver of our failure to replace our former Chief Executive Officer within 90 days of his resignation.
	On August 12, 2013, we also entered into a Waiver and Third Amendment to our Credit Agreement with ROS whereby we agreed to pay an additional fee in the amount of 2% (in addition to our prior fee of 1.5%, for a total of 3.5%) of the aggregate amount of any principal payment, prepayment or repayment in exchange for a waiver of our failure to achieve the minimum revenue required in the second quarter of 2013.
	On August 30, 2013, we entered into a Fourth Amendment to our Credit Agreement with ROS to revise the Board observer rights we granted to ROS.
	On November 14, 2013, we entered into a Waiver and Fifth Amendment to our Credit Agreement with ROS whereby we agreed to issue 150,000 shares of common stock to an affiliate of ROS in exchange for a waiver of our failure to achieve the minimum required revenue for the third quarter of 2013 and a reduction of future quarterly minimum revenue thresholds.
	On March 6, 2014, we entered into a Sixth Amendment to our Credit Agreement with ROS whereby we borrowed an additional $4 million under our Credit Agreement with ROS and agreed to issue 150,000 shares to an affiliate of ROS.  We plan to use the proceeds for working capital and general corporate purposes.
	Long-term debt consists of the following:
		December 31,		December 31,
		2014		2013
	Loan payable to ROS Acquisition Offshore, LIBOR plus 12.13% maturing August 2019	$	24,000,000	$	20,000,000
	Adjustment fee payable to ROS Acquisition Offshore, due in August 2019		700,000		700,000
	6.00% loan payable to Valley Bank of Belgrade, $10,746 monthly payments including interest, maturing December 24, 2030; secured by building		1,325,814		1,375,030
			26,025,814		22,075,030
	Less: current portion		-50,671		-47,727
	Debt discount		-5,104,813		-5,642,058
	Long-term debt	$	20,870,330	$	16,385,245
	The following is a summary of maturities due on the debt as of December 31, 2014:
	2015	$	50,609
	2016		2,112,064
	2017		8,290,378
	2018		8,293,897
	2019		6,239,295
	2020 and thereafter		1,039,571
	Total	$	26,025,814
	The following is a summary of estimated future royalty payments as of December 31, 2014:
	2015	$	1,000,750
	2016		1,229,250
	2017		1,360,250
	2018		1,462,750
	2019		1,575,250
	Thereafter		5,626,325
	Total	$	12,254,575

StockBased_Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	(9)           Stock-Based Compensation
	Our Equity Incentive Plan ("The Plan") provides for stock awards, including options and performance stock awards, to be granted to employees, consultants, independent contractors, officers and directors. The purpose of the Plan is to enable us to attract, retain and motivate key employees, directors and, on occasion, independent consultants, by providing them with stock options and restricted stock grants. Stock options granted under the Plan may be either incentive stock options to employees, as defined in Section 422A of the Internal Revenue Code of 1986, or non-qualified stock options. The Plan is administered by the compensation committee of our Board of Directors. The administrator of the Plan has the power to determine the terms of any stock options granted under the Plan, including the exercise price, the number of shares subject to the stock option and conditions of exercise. Stock options granted under the Plan are generally not transferable, vest in installments over the requisite service period and are exercisable during the stated contractual term of the option only by such optionee. The exercise price of all incentive stock options granted under the Plan must be at least equal to the fair market value of the shares of common stock on the date of the grant. 900,000 shares are authorized under the Plan and at December 31, 2014, we had approximately 107,700 shares available for issuance. Shares issued under the Plan may be authorized, but unissued or reacquired shares.
	Stock compensation expense recognized in the statement of operations for the year ended December 31, 2014 and 2013 is based on awards ultimately expected to vest and reflects an estimate of awards that will be forfeited. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
	The estimated fair value of stock options granted is done using the Black-Sholes-Merton method applied to individual grants. The Company utilizes historical employee termination behavior to determine the estimated forfeiture rates. If the actual forfeitures differ from those estimated by management, adjustments to compensation expense will be made in future periods.  An assumed forfeiture rate of 20% was used for the year ended 2014.
	The estimated fair value of stock options granted is done using the Black-Sholes-Merton method applied to individual grants. Key assumptions used to estimate the fair value of stock awards are as follows:
	¨	Risk-Free Rate: The risk-free rate is determined by reference to U.S. Treasury yields at or near the time of grant for time periods similar to the expected term of the award. We used a weighted-average rate of 1.92% and 1.16% for years ended December 31, 2014 and December 31, 2013, respectively.
	¨	Expected Term: We do not have adequate history to estimate an expected term of stock-based awards, and accordingly, we use the simplified method as prescribed by Staff Accounting Bulletin 107 to determine an expected term. We used a weighted-average expected term of 5.4 and 6.2 years for the years ended December 31, 2014 and December 31, 2013, respectively.
	¨	Volatility: We estimate expected volatility based on peer-companies as prescribed by ASC 718. We used a weighted-average volatility rate of 57% and 66% for the years ended December 31, 2014 and December 31, 2013, respectively.
	¨	Dividend Yield: The dividend yield assumption is based on our history and expectation of dividend payouts and was 0% as of December 31, 2014 and 2013.
	In August 2013, the Company granted our Chief Executive Officer an option to purchase 200,000 shares of our common stock outside of the Plan, and in July 2014, the Company granted our President an option to purchase 55,000 shares of our common stock outside of the Plan (collectively the “Non-Plan Grants”).
	Stock option activity under the Plan, plus the Non-Plan Grants, was as follows:
			2014						2013
					Weighted		Weighted				Weighted		Weighted
					Average		Average Fair				Average		Average Fair
					Exercise		Value at Grant				Exercise		Value at Grant
			Shares		Price		Date		Shares		Price		Date
	Outstanding at January 1			758,328	$	14.9	$	8.6		526,653	$	20.2	$	10.3
	Granted			169,300		5.78		2.65		333,125		6.3		5.3
	Exercised			-6,666		10		0.04		-23,000		1		0.6
	Cancelled or expired			-225,626		11.38		6.07		-78,450		17.6		8.9
	Outstanding at December 31			695,336	$	11.09	$	5.35		758,328	$	14.9	$	8.6
	Exercisable at December 31			311,080	$	15.25	$	7.35		264,272	$	20.1	$	10.3
	The aggregate intrinsic value of options outstanding as of December 31, 2014 is approximately $23,345. The aggregate intrinsic value of exercisable options as of December 31, 2014 is approximately $23,345. As of December 31, 2014, there were 384,256 unvested options with a weighted average fair value at the grant date of $12.54 per option. As of December 31, 2014, there is approximately $795,221 of compensation expense related to unvested awards not yet recognized.
	On May 24, 2013, the Company issued 33,500 restricted stock awards to certain employees. These restricted shares vested after one year and were issued when the stock price was $6.80 per share. The total expense of $227,800 was recognized ratably over the vesting period in General and Administrative and Sales and Marketing Expenses.
	From time to time we may grant stock options and restricted stock grants to consultants. We account for consultant stock options in accordance with ASC 505-50. Consulting expense for the grant of stock options to consultants is determined based on the estimated fair value of the stock options at the measurement date as defined in ASC 505-50 and is recognized over the vesting period.
	The Company recognized non-cash consulting expense for the years ended 2014 and 2013 as $135,075 and a negative $5,117, respectively.
	Total share based compensation recognized for employees and consultants were $935,316 and $975,905 for the years ended December 31, 2014 and 2013, respectively.
	The following table summarizes restricted stock award activity during the year ended December 31, 2014:
			Shares
	Outstanding at January 1, 2013			73,390
	Cancelled			-27,868
	Vested			-14,672
	Outstanding at January 1, 2014			30,850
	Awarded			39,312
	Cancelled			-30,850
	Vested			-
	Outstanding at December 31, 2014			39,312
	On November 10, 2014, the company issued 39,312 shares of restricted stock to the independent Directors of the Company. These restricted shares vest on July 1, 2015 and were issued when the stock price was $4.07 per share. The total expense of $160,000 was recognized ratably over the period to General and Administrative expense.

Warrants

Warrants	12 Months Ended
	Dec. 31, 2014
Warrants and Rights Note Disclosure [Abstract]
Warrants	(10)           Warrants
	The following table summarizes our warrant activities for the period ended December 31, 2014:
					Weighted
					Average
					Exercise
		Shares			Price
	Outstanding as of January 1, 2013		732,167		$	22
	Issued		435,222			7.2
	Expired		-79,569			20
	Outstanding at January 1, 2014		1,087,820		$	16.2
	Issued		571,500			7.12
	Expired		-4,000			20
	Outstanding at December 31, 2014		1,655,320			13.06
	We utilize a lattice model to determine the fair market value of the warrants accounted for as liabilities. The valuation model accommodates the probability of exercise price adjustment features as outlined in the warrant agreements. We recorded an unrealized gain of $1,736,053 resulting from the change in the fair value of the warrant derivative liability for 2014. Under the terms of the warrant agreement, at any time while the warrant is outstanding, the exercise price per share can be reduced to the price per share of future subsequent equity sales of our common stock or a common stock equivalent that is lower than the exercise price per share as stated in the warrant agreement.
	The estimated fair value was derived using the lattice model with the following weighted-average assumptions:
		Year ended
		December 31,
		2014				2013
	Value of underlying common stock (per share)	$	3.03			$	5
	Risk free interest rate		0.8	%			0.89	%
	Expected term		5.00 years				5.56 years
	Dividend yield		0				0
	Volatility		75	%			65	%
	The following table summarizes our activities related to warrants accounted for as a derivative liability for the year ended December 31, 2014 and 2013:
		2014			2013
	Balance at January 1, 2014		600,192			164,971
	Derivative warrants issued		571,500			435,221
	Derivative warrants exercised		-			-
	Balance at December 31, 2014		1,171,692			600,192

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	(11)   Commitments and Contingencies
	Operating Leases
	We lease two office facilities under non-cancelable operating lease agreements with expiration dates in 2019 and 2023. We have the option to extend both the leases for another ten year term and for one facility, we have the right of first refusal on any sale. We lease an additional office facility under a month-to-month arrangement. Future minimum payments for the next five years and thereafter as of December 31, 2014, under these leases, are as follows:
	2015	$	334,317
	2016		269,400
	2017		269,400
	2018		269,400
	2019		269,400
	Thereafter		559,000
	Total	$	1,970,917
	Rent expense was $365,000 and $283,000 for the years ended December 31, 2014 and 2013, respectively. Rent expense is determined using the straight-line method of the minimum expected rent paid over the term of the agreement. We have no contingent rent agreements.
	Indemnifications
	Our arrangements generally include limited warranties and certain provisions for indemnifying customers against liabilities if our products or services infringe a third-party's intellectual property rights. To date, we have not incurred any material costs as a result of such warranties or indemnifications and have not accrued any liabilities related to such obligations in the accompanying financial statements.
	We have also agreed to indemnify our directors and executive officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by any of these persons in any action or proceeding to which any of those persons is, or is threatened to be, made a party by reason of the person's service as a director or officer, including any action by us, arising out of that person's services as our director or officer or that person's services provided to any other company or enterprise at our request.
	Pending and Threatened Litigation
	On March 17, 2014, a complaint was served on the Company in the following state court action in the District Court for the County of Arapahoe, State of Colorado: Robert Taggart v. Guy Cook, Bacterin International, Inc., a Nevada Corporation and Bacterin International Holdings, Inc., a Delaware corporation, Civil Action No. 14CV30401. The complaint involves claims under an employment agreement between plaintiff and the Company seeking commissions on Company sales, a commission on funds obtained by the Company as a result of a reverse merger and vesting of certain stock options. Plaintiff seeks damages in excess of $5 million. The Company believes this case lacks legal merit and has filed counterclaims for plaintiff’s breach of his employment agreement and breach of his duty of loyalty to the Company, asserting the right to recover all compensation paid to Plaintiff during his employment as well as other damages.
	On July 9, 2014, a complaint was served on the Company in the following action in the United States District Court, District of New Jersey:  Middlebury Securities, LLC v. Bacterin International, Inc., Case Number 2:14-CV-03905-WJM-MF.  The complaint alleges that Bacterin owes Middlebury an $80,000 fee, along with $80,000 in warrants, in connection with the March 6, 2014 extension of credit by ROS.   Bacterin believes this case lacks merit because there is no agreement between the parties regarding the transaction in question.
	On July 14, 2014, a complaint was served on the Company in the following action in the United States Bankruptcy Court, Southern District of New York, In re:  Rodman & Renshaw, LLC, Debtor, Case No. 13-10087 (REG):  YANN GERON, Chapter 7 Trustee of the Estate of Rodman & Renshaw, LLC, Plaintiff, against Bacterin International Holdings, Inc.  The complaint alleges that Bacterin owes a $150,000 investment banking fee in connection with Bacterin’s April 2012 accounts receivable credit facility with MidCap Financial LLC.  Bacterin believes this case lack merit because the accounts receivable credit facility was not a debt or equity security covered by the engagement letter.
	NYSE MKT Deficiency Notice
	On May 13, 2013, we received a deficiency notice from the NYSE MKT notifying us that we are not in compliance with Section 1003(a)(iii) of the Company Guide with stockholders’ equity of less than $6,000,000 and net losses in five of our most recent fiscal years and Section 1003(a)(ii) with stockholders’ equity of less than $4,000,000 and net losses in three of our four most recent fiscal years. On June 12, 2013 we submitted a plan to regain compliance with the continued listing requirements, and on June 21, 2013 the NYSE MKT informed us of the acceptance of our plan and gave us an extension until November 13, 2014 to regain compliance with the continued listing standards. On November 19, 2013, we received another letter from the NYSE MKT notifying us that we are not in compliance with Section 1003(a)(i) of the Company Guide with stockholders’ equity of less than $2,000,000 as of September 30, 2013 and net losses in two of three of our most recent fiscal years, and we submitted an amended plan to regain compliance. On November 14, 2014, we received a letter notifying us that the staff of NYSE Regulation, Inc. (the “Staff”) determined to commence proceedings to delist our common stock from the NYSE MKT because we did not cure our non-compliance with Sections 1003(a)(i), (ii) and (iii) of the NYSE MKT Company Guide by the end of the maximum 18 month compliance period, which expired on November 13, 2014. We appealed the Staff’s delisting determination and attended a hearing on January 21, 2015. On January 26, 2015, following our January 21, 2015 hearing with a Listing Qualifications Panel (the “Panel”) of the NYSE MKT LLC’s Committee on Securities (the “Committee”), we received a letter notifying us that the Panel affirmed the determination of the Staff to delist our common stock. We have requested a full Committee review of the Panel’s decision. If our common stock is delisted from the NYSE MKT, our stock price might be negatively affected, some shareholders may sell their shares, and we may not be able to attract institutional investors in future financing transactions. There can be no assurance that our common stock will remain listed on the NYSE MKT,

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	(12)           Income Taxes
	The Company’s provision for income taxes differs from applying the statutory U.S. federal income tax rate to income before taxes. The primary difference results from providing for state income taxes and from deducting certain expenses for financial statement purposes but not for federal income tax purposes.
	The components of income (loss) before provision for income taxes consist of the following:
		Year Ended December 31,
		2014		2013
	United States	$	-10,507,869	$	-12,693,125
		$	-10,507,869	$	-12,693,125
	The components of the income tax provision are as follows:
		Year Ended December 31,
		2014		2013
	Current:
	Federal	$	-	$	-
	State		-		-
	Total current		-		-
	Deferred:
	Federal		-		-
	State		-		-
	Total deferred		-		-
		$	-	$	-
	The reconciliation of income tax attributable to operations computed at the U.S. Federal statutory income tax rate of 35% to income tax expense is as follows:
		Year Ended December 31,
		2014		2013
	Statutory Federal tax rate	$	-3,677,754	$	-4,442,594
	Valuation allowance		4,909,776		4,112,338
	State income taxes, net of Federal benefit		-368,826		-528,034
	Change in state income tax rate		277,076		574,964
	Provision to return adjustment		-505,423		-
	Change in Warrant Derivative Liability		-668,554		-342,666
	Stock issued in exchange for debt waiver		-		581,649
	Nondeductible meals, entertainment and other expense		33,705		44,343
		$	-	$	-
	Deferred tax assets and liabilities are as follows:
		At December 31,
		2014		2013
	Deferred tax assets:
	Current deferred tax assets
	Accrued liability for vacation	$	102,643	$	85,599
	Bad debt reserve		536,440		512,941
	Charitable contributions carryforward		33,124		19,746
	Inventory reserve		1,098,333		895,760
	Reserve – assets held for sale		351,423		-
	Restricted stock compensation		-		82,640
	Total current deferred tax assets		2,121,963		1,596,686
	Valuation Allowance		-2,121,963		-1,596,686
	Net current deferred tax assets		-		-
	Noncurrent deferred tax assets
	Net operating loss carryovers		18,200,823		14,863,919
	Stock warrants		131,891		134,117
	Stock option compensation		1,594,460		1,307,998
	Goodwill amortization		82,212		90,868
	Debt discount and waiver amortization		1,076,926		455,916
	Depreciation		244,004		97,492
	Amortization		30,290		25,797
	Total noncurrent deferred tax assets		21,360,606		16,976,107
	Valuation allowance		-21,360,606		-16,976,107
	Net noncurrent deferred tax assets		-		-
	Net deferred tax assets	$	-	$	-
	The ultimate realization of deferred tax assets is dependent upon the existence, or generation, of taxable income in the periods when those temporary differences and net operating loss carryovers are deductible. Management considers the scheduled reversal of deferred tax liabilities, taxes paid in carryover years, projected future taxable income, available tax planning strategies, and other factors in making this assessment. Based on available evidence, management does not believe it is more likely than not that all of the deferred tax assets will be realized. Accordingly, the Company has established a valuation allowance equal to the net realizable deferred tax assets. The valuation allowance increased by $4,909,776 and $4,112,338 in 2014 and 2013, respectively.
	At December 31, 2014 and 2013, the Company had total domestic Federal and state net operating loss carryovers of approximately $47,262,588 and $37,976,891, respectively. Federal net operating loss carryovers expire at various dates between 2025 and 2034, while state net operating loss carryovers expire between 2025 and 2034 .
	Under the Tax Reform Act of 1986, as amended, the amounts of and benefits from net operating loss carryovers and research and development credits may be impaired or limited in certain circumstances. Events which cause limitations in the amount of net operating losses that the Company may utilize in any one year include, but are not limited to, a cumulative ownership change of more than 50%, as defined, over a three year period. The Company does not believe that such an ownership change has occurred in 2014 or 2013.
	The 2011 through 2014 tax years remain open to examination by the Internal Revenue Service and the 2009 to 2014 tax years remain open to the Montana Department of Revenue and various other state tax agencies. These taxing authorities have the authority to examine those tax years until the applicable statute of limitations expire.
	The Company did not recognize any interest or penalties related to income taxes for the years ended December 31, 2014 and 2013.

Employee_Benefit_Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Employee Benefit Plans	(13) Employee Benefit Plans
	The Company has a 401(k) retirement plan.  Qualified employees may defer their salary and the deferrals are matched up to 2%.  The plan covers substantially all full-time employees.  Under the terms of the plan, participants may contribute up to the lower of $17,500 of their salary or the statutorily prescribed limit to the plan.  Employees are eligible after six months of employment and may enroll twice a year in January and July.

Supplemental_Disclosure_of_Cas

Supplemental Disclosure of Cash Flow Information	12 Months Ended
	Dec. 31, 2014
Supplemental Cash Flow Elements [Abstract]
Supplemental Disclosure of Cash Flow Information	(14)   Supplemental Disclosure of Cash Flow Information
	Supplemental cash flow information is as follows:
		Twelve Months Ended
		December 31,
		2014		2013
	Supplemental disclosure of cash flow information
	Cash paid during the period for:
	Interest	$	3,192,854	$	2,681,459
	Non-cash activities:
	Settlement of SeaArk accounts receivable	$	-	$	1,829,647
	Inventory received in SeaArk settlement	$	-	$	409,838
	Write-off of SeaArk allowance for doubtful accounts	$	-	$	1,419,809
	Issuance of Warrants related to stock issuance	$	1,461,796	$	1,485,313
	Increase in long-term debt, ROS adjustment fee	$	-	$	700,000
	Issuance of shares, ROS adjustment fee	$	-	$	630,000
	Issuance of shares related to debt issuance	$	1,094,999	$	-
	Issuance of restricted stock to employees	$	136,977	$	-

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions	(15)   Related Party Transactions
	Guy Cook was our President, Chief Executive Officer and Chairman of our Board of Directors until April 5, 2013, when he resigned. Mr. Cook has advised us that he is currently an owner and executive officer of Lattice Biologics, Inc., a competitor of ours that was formerly known as International Biologics, LLC. International Biologics, LLC was a former customer of Bacterin and was indebted to us in the amount of approximately $33,468, which was paid.
	Mr. Cook assisted unrelated parties in the initial capitalization of Holgan, LLC, a former stocking distributor that purchased a bulk shipment of products from Bacterin at a discount in 2012 (“Holgan”). Holgan subsequently obtained financing from Lacuna Hedge Fund LLLP (“Lacuna”), formerly a significant Bacterin shareholder. Holgan failed to fully pay for the products it acquired from Bacterin and defaulted under its credit agreement with Lacuna. We reached a settlement with Lacuna whereby we paid Lacuna $350,000 in exchange for a release of all claims Lacuna may have against Bacterin and its current and former directors and officers, and we understand that Mr. Cook’s new company, Lattice, purchased substantially all of the Bacterin products held by Holgan, with the proceeds to be paid to Lacuna.
	Mr. Cook’s spouse was employed by Bacterin as the Director of Human Resources until April 9, 2013. Mr. Cook, together with his adult children, owned and operated Silver Forest Fund, LP (“Silver Forest”), a former distributor of Bacterin products. We terminated the contractual relationship with Silver Forest on October 24, 2013. In 2012, Silver Forest purchased Bacterin products from an unaffiliated former distributor and subsequently exchanged some of those products for different Bacterin products of equivalent value. Other than product exchanges and payment of amounts owed by the non-affiliated distributor, we are not aware of any other direct transactions between Bacterin and Silver Forest.
	Mr. Cook also formerly served as a board member of West Coast Tissue Services (“WCTS”) and American Donor Services (“ADS”). Mr. Cook did not receive any compensation for his board service from either entity. Darrel Holmes, our Chief Operating Officer, and Mitchell Godfrey, a former director, also serve on the board of ADS, and Mr. Godfrey also serves as secretary and treasurer for ADS. Mssrs. Godfrey and Holmes receive $5,000 per year for their service to ADS. ADS and WCTS recover tissue from donors.  We reimburse them for their recovery fees, which are comprised primarily of labor costs. The approximate aggregate amount of all transactions with WCTS for the years ended December 31, 2014 and 2013 was $98,600 and $840,100, respectively, and the approximate aggregate amount of all transactions with ADS for the years ended December 31, 2014 and 2013 was $2,406,926 and $2,055,523, respectively. These relationships have benefited us, as these entities provide us with donors, thus insuring that we have a pipeline of current and future donors, which is necessary to our success.
	Unless delegated to the Compensation Committee by the Board of Directors, the Audit Committee or the disinterested members of the full Board of Directors reviews and approves all related party transactions.

Subsequent_Event

Subsequent Event	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Event	(16)   Subsequent Event
	On March 16, 2015, we entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”) which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $10.0 million of shares of our common stock over the 24-month term after a registration statement is declared effective by the U.S. Securities and Exchange Commission (“SEC”) relating to the transaction. The stock purchase transactions are at the Company’s option. Concurrently with entering into the Purchase Agreement, we also entered into a Registration Rights agreement with Aspire Capital (the “Registration Rights Agreement”), in which we agreed to file one or more registration statements to register under the Securities Act of 1933, as amended (the “Securities Act”), the sale of the shares of our common stock that may be issued to Aspire Capital under the Purchase Agreement. Under the Purchase agreement, within five business days after approval of the transaction by the NYSE MKT, we also agreed to sell, and Aspire Capital agreed to buy, 207,182 shares of our common stock (the "Initial Purchase Shares") for $750,000 in aggregate proceeds. We also agreed at such time to issue to Aspire Capital 154,189 shares of our common stock as a commitment fee (the "Commitment Shares").
	After a registration statement is declared effective by the SEC relating to the transaction, we have the right to sell up to an additional $9,250,000 of our common stock in the aggregate to Aspire Capital over a 24-month period. More specifically, we have the right, in our sole discretion, to present Aspire Capital with purchase notices (each, a “Purchase Notice”), directing Aspire Capital (as principal) to purchase up to 50,000 shares of our common stock, per trading day, provided that the aggregate price of each such purchase shall not exceed $500,000 per trading day at a per share price (the “Purchase Price”) equal to the lesser of:
	• the lowest sale price of our common stock on the purchase date; or
	• the arithmetic average of the three lowest closing sale prices for our common stock during the ten consecutive trading days ending on the trading day immediately preceding the purchase date.
	In addition, we also have the right to present Aspire Capital with volume-weighted average price purchase notices directing Aspire Capital to purchase an amount of stock equal to up to 30% of the aggregate shares of our common stock traded on the NYSE MTK on the next trading day subject to the terms, conditions and limitations in the Purchase Agreement.
	The Purchase Agreement may be terminated by us at any time, at our discretion, without any penalty or cost to us. The Purchase Agreement also provides for customary events of default, upon the occurrence of which Aspire Capital may terminate the Purchase Agreement. Aspire Capital has agreed that neither it nor any of its agents, representatives and affiliates shall engage in any direct or indirect short-selling or hedging of our common stock during any time prior to the termination of the Purchase Agreement. Any proceeds we receive under the Purchase Agreement are expected to be used for general working capital.

Business_Description_and_Summa1

Business Description and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Description	Business Description
	The accompanying consolidated financial statements include the accounts of Bacterin International Holdings, Inc., a Delaware corporation, and its wholly owned subsidiary, Bacterin International, Inc., a Nevada corporation, (collectively, the “Company” or “Bacterin”). All intercompany balances and transactions have been eliminated in consolidation. Bacterin develops, manufactures and markets biologics products to domestic and international markets.  Bacterin’s proprietary methods are used in human allografts to create scaffolds and promote bone and other tissue growth.  These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain with a facet joint stabilization, promotion of bone growth in foot and ankle surgery, promotion of skull healing following neurosurgery and regeneration in knee and other joint surgeries.
	Bacterin also develops and licenses coatings for various medical device applications.  As of December 31, 2014, Bacterin made a strategic decision to discontinue the medical device coatings business which resulted in an impairment of related assets. See Note 4, “Impairment of Assets”.
	An operating segment is a component of an enterprise whose operating results are regularly reviewed by the enterprise’s chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance. The primary performance measure used by management is net income or loss. Up until December 31, 2014, the Company operated two distinct lines of business consisting of the biologics and the device divisions. With the strategic exit from the devices business as of December 31, 2014, the Company will be operating as a single business segment in 2015.
	The Company's revenue is derived principally from the sale of its biologics products. The markets in which the Company competes are highly competitive and rapidly changing. Significant technological advances, changes in customer requirements, or the emergence of competitive products with new capabilities or technologies could adversely affect the Company's operating results. The Company's business could be harmed by a decline in demand for, or in the prices of, its products or as a result of, among other factors, any change in pricing or distribution model, increased price competition, changes in government regulations or a failure by the Company to keep up with technological change.  Further, a decline in available tissue donors could have an adverse impact on our business.
Reverse Stock Split	Reverse Stock Split
	The Company completed a 1:10 reverse split of its common stock, effective at the close of business on Friday, July 25, 2014 and in effect for trading purposes on Monday, July 28, 2014. The reverse stock split was approved by the Company's shareholders at the 2014 Annual Meeting of Shareholders on June 11, 2014.  All references to common shares, stock option, restricted stock units, warrants, and per share amounts have been retroactively adjusted to reflect the reverse stock split for all periods presented.
Public Offering	Public Offering
	In August 2014, the Company offered 1,143,000 shares of its common stock at $5.70 per share and warrants to purchase 571,500 shares of its common stock at an exercise price of $7.12 per share to the public.  Gross proceeds of the offering were approximately $6.5 million. Net proceeds from the offering were approximately $5.9 million and will be used for working capital and general corporate purposes, including the continued expansion of the company's sales force and increasing inventory levels to support anticipated future growth.  The offering closed on August 6, 2014.
	The warrants have a five year term and expire on August 6, 2019.  The Company utilizes a lattice model to determine the fair market value and accounts for these warrants as a derivative liability (see "Derivative Instruments" below).  Also, see Note 10, "Warrants"  below.
Concentrations and Credit Risk	Concentrations and Credit Risk
	The Company’s accounts receivable are due from a variety of health care organizations and distributors throughout the world. Approximately 98% of sales were in the United States for 2014 and 2013.  No single customer accounted for more than 10% of revenue or accounts receivable for 2014 and 2013.  The Company provides for uncollectible amounts when specific credit issues arise. Management’s estimates for uncollectible amounts have been adequate during prior periods, and management believes that all significant credit risks have been identified at December 31, 2014.
	Revenue by geographical region is as follows:
		Year ended
		December 31,
		2014		2013
	United States	$	34,643,571	$	32,458,822
	Rest of World		688,241		584,592
		$	35,331,812	$	33,073,414
Use of Estimates	Use of Estimates
	The preparation of the financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Significant estimates include the carrying amount of property and equipment and intangible assets; valuation allowances for trade receivables and deferred income tax assets; valuation of the warrant derivative liability; inventory reserve; royalty liability; and estimates for the fair value of stock options grants and other equity awards upon which the Company determines stock-based compensation expense. Actual results could differ from those estimates.
Reclassifications	Reclassifications
	Certain comparative balances for year ended December 31, 2013 have been reclassified to make them consistent with the current year presentation. The reclassifications had no effect on the net income for 2013.
Cash and Cash Equivalents	Cash and Cash Equivalents
	The Company considers all highly liquid investments purchased with an original maturity date of three months or less to be cash equivalents.  Cash equivalents are recorded at cost, which approximates market value. At times the Company maintains deposits in financial institutions in excess of federally insured limits.
Accounts Receivable	Accounts Receivable
	Accounts receivable represents amounts due from customers for which revenue has been recognized. Normal terms on trade accounts receivable are net 30 days and some customers are offered discounts for early pay.   The Company performs credit evaluations when considered necessary, but generally does not require collateral to extend credit.
	The allowance for doubtful accounts is the Company's best estimate of the amount of probable credit losses in the Company's existing receivables. The Company determines the allowance based on factors such as historical collection experience, customer's current creditworthiness, customer concentration, age of accounts receivable balance, general economic conditions that may affect a customer's ability to pay and management judgment. Actual customer collections could differ from estimates. Account balances are charged to the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Provisions to the allowance for doubtful accounts are charged to expense. The Company does not have any off-balance sheet credit exposure related to its customers.
Inventories	Inventories
	Inventories are stated at the lower of cost or market.  Cost is determined using the specific identification method and includes materials, labor and overhead. The Company calculates an inventory reserve for estimated obsolescence or excess inventory based on historical usage and sales, as well as assumptions about future demand for its products. These estimates for excess and obsolete inventory are reviewed and updated on a quarterly basis. Increases in the inventory reserves result in a corresponding expense, which is recorded to cost of tissue and medical devices sales. Inventories where the sales cycle is estimated to be beyond twelve months are classified as Non-current inventories.
Property and Equipment	Property and Equipment
	Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to seven years for computers and equipment, and 30 years for buildings. Leasehold improvements are depreciated over the shorter of their estimated useful life or the remaining term of the lease. Repairs and maintenance are expensed as incurred.
Goodwill	Goodwill
	Goodwill represents the excess of costs over fair value of assets of businesses acquired. Goodwill and intangible assets acquired in a purchase business combination and determined to have indefinite useful lives are not amortized, instead are tested for impairment at least annually and whenever events or circumstances indicate the carrying amount of the asset may not be recoverable. The Company conducts its annual impairment test on December 31 of each year. In its evaluation of goodwill in 2013, the Company performed an assessment of qualitative factors to determine if it is more-likely-than-not that goodwill might be impaired and whether it is necessary to perform the two-step goodwill impairment. See Note 4, “Impairment of Assets”.
Derivative Instruments	Derivative Instruments
	The Company accounts for its derivative instruments in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 815 “Accounting for Derivative Instruments and Hedging Activities”. The only derivative instruments presented in the accompanying consolidated financial statements relate to warrants issued in connection with certain debt and equity financings. The Company has not designated its warrant derivative liability as a hedging instrument as described in ASC 815 and any change in the fair market value of the warrant derivative liability is recognized in the consolidated statement of operations during the period of change. See Note 10, “Warrants” below.
Intangible Assets	Intangible Assets
	Intangible assets with estimable useful lives must be amortized over their respective estimated useful lives to their estimated residual values, and reviewed for impairment whenever events or circumstances indicate their carrying amount may not be recoverable. Intangible assets include trademarks and patents and include costs to acquire and protect Company patents. Intangible assets are carried at cost less accumulated amortization. The Company amortizes these assets on a straight-line basis over their estimated useful lives of fifteen years.
Other Assets	Other Assets
	Other Assets consist of the short-term and the long-term portion of prepaid expenses, security deposits, the capitalized portion of debt related issuance costs and kits that are used in the implantation of certain biologic products. The items are stated at cost and in the case of debt related issuance costs and kits are amortized on a straight line basis over their estimated useful lives.
Accounts Payable - Related Party	Accounts Payable - Related Party
	Accounts payable to a related party includes amounts due to American Donor Services and West Coast Tissue Services, as suppliers of donors to the Company for 2014 and 2013. See Note 15, “Related Party Transactions” below.
Revenue Recognition	Revenue Recognition
	Revenue is recognized when all of the following criteria are met: a) the Company has entered into a legally binding agreement with the customer; b) the products or services have been delivered; c) the Company's fee for providing the products and services is fixed or determinable; and d) collection of the Company’s fee is probable.
	The Company’s policy is to record revenue net of any applicable sales, use, or excise taxes.  If an arrangement includes a right of acceptance or a right to cancel, revenue is recognized when acceptance is received or the right to cancel has expired.
	The Company ships to certain customers under consignment arrangements whereby the Company’s product is stored by the customer.  The customer is required to report the use to the Company and upon such notice, the Company invoices the customer and revenue is recognized when above criteria have been met.
	The Company also receives royalty revenue from third parties related to licensing agreements. The Company has royalty agreements with RyMed and Bard Access Systems. Revenue under these agreements represented less than 0.5% of total revenue for the years ended December 31, 2014 and 2013.
Non-Cash Consulting Expense	Non-Cash Consulting Expense
	From time to time, the Company issues restricted stock awards to consultants and advisors to the Company. These awards are measured at fair value at each reporting date, recognized ratably over the vesting period and are recorded in non-cash consulting expense.
Advertising Costs	Advertising Costs
	The Company expenses advertising costs as incurred. The Company had advertising expense of $34,970 and $47,000 for the years ended December 31, 2014 and 2013, respectively.
Research and Development	Research and Development
	Research and development costs, which are principally related to internal costs for the development of new technologies and processes for tissue and coatings, are expensed as incurred.
Income Taxes	Income Taxes
	The Company accounts for income taxes under the asset and liability method of accounting for deferred taxes as prescribed under FASB ASC 740, "Accounting for Income Taxes".  Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. When applicable, a valuation allowance is established to reduce any deferred tax asset when it is determined that it is more likely than not that some portion of the deferred tax asset will not be realized. ASC 740 also requires reporting of taxes based on tax positions that meet a more-likely-than-not standard and that are measured at the amount that is more-likely-than-not to be realized. Differences between financial and tax reporting which do not meet this threshold are required to be recorded as unrecognized tax benefits. ASC 740 also provides guidance on the presentation of tax matters and the recognition of potential IRS interest and penalties. The Company classifies penalty and interest expense related to income tax liabilities as an income tax expense. There are no significant interest and penalties recognized in the statement of operations or accrued on the balance sheet. See Note 12, “Income Taxes” below.
Long-Lived Assets	Long-Lived Assets
	Long-lived assets, including intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. See Note 4, “Impairment of Assets”.
Net Loss Per Share	Net Loss Per Share
	Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding. Shares issued during the period and shares reacquired during the period are weighted for the portion of the period that they were outstanding. Diluted net income (loss) per share is computed in a manner consistent with that of basic earnings per share while giving effect to all potentially dilutive common shares outstanding during the period, which include the assumed exercise of stock options and warrants using the treasury stock method.  Diluted net loss per share was the same as basic net loss per share for the years ended December 31, 2014 and 2013, as shares issuable upon the exercise of stock options and warrants were anti-dilutive as a result of the net losses incurred for those periods.  Dilutive earnings per share are not reported as their effects of including 2,350,656 and 1,846,148 outstanding stock options and warrants for the years ended December 31, 2014 and 2013, respectively, are anti-dilutive.
Stock-Based Compensation	Stock-Based Compensation
	The Company records stock-compensation expense according to the provisions of FASB ASC 718 “Compensation – Stock Compensation”.  Under ASC 718, stock-based compensation costs are recognized based on the estimated fair value at the grant date for all stock-based awards.  The Company estimates grant date fair values using the Black-Scholes-Merton option pricing model, which requires assumptions of the life of the award and the stock price volatility over the term of the award.  The Company records Compensation cost of stock-based awards using the straight line method, which is recorded into earnings over the vesting period of the award.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	The carrying values of financial instruments, including trade accounts receivable, accounts payable, other accrued expenses and long-term debt, approximate their fair values based on terms and related interest rates.
	The Company follows a framework for measuring fair value. The framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:
	Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets.
	Level 2: Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
	Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.
	A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. During the years ended December 31, 2014 and 2013, there was no reclassification in financial assets or liabilities between Level 1, 2 or 3 categories.
	The following tables set forth by level, within the fair value hierarchy, our assets and liabilities as of the years ended December 31, 2014 and December 31, 2013, respectively, that are measured at fair value on a recurring basis:
	Accrued stock compensation
		As of		As of
		December 31,		December 31,
		2014		2013
	Level 1	$	-	$	211,212
	Level 2		-		-
	Level 3		-		-
	The valuation technique used to measure fair value of the accrued stock compensation is based on quoted stock market prices.
	Warrant derivative liability
		As of		As of
		December 31,		December 31,
		2014		2013
	Level 1		-		-
	Level 2		-		-
	Level 3	$	1,320,371	$	1,594,628
	The valuation technique used to measure fair value of the warrant liability is based on a lattice model and significant assumptions and inputs determined by us.
	Level 3 Changes
	The following is a reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the year ending December 31, 2014:
	Warrant derivative liability
	Balance at January 1, 2014	$	1,594,628
	Warrants issued with stock offering		1,461,796
	Gain recognized in earnings		-1,736,053
	Balance at December 31, 2014	$	1,320,371
	During the year ended December 31, 2014, the Company did not change any of the valuation techniques used to measure its liabilities at fair value.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 supersedes the revenue recognition guidance in Topic 605, Revenue Recognition. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods and services to customers in an amount that reflects the consideration to which the entity expects to be entitled in the exchange for those goods or services. This standard is effective for annual reporting periods beginning after December 15, 2016. ASU 2014-09 is not expected to have a material impact on our consolidated financial position, results of operations, or cash flows.
	In August 2014, FASB issued ASU No. 2014-15, Preparation of Financial Statements - Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern.  Under GAAP, continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity's liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting.  If and when an entity's liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements-Liquidation Basis of Accounting.  Even when an entity's liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity's ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events.  The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter.  Early application is permitted. The Company will evaluate the going concern considerations in this ASU, but has not elected early application.
	In November 2014, FASB issued ASU No. 2014-08, Presentation of Financial Statements (Topic 201) and Property, Plant and Equipment (Topic 360) - Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. The amendments in this Update are effective for the annual period ending after December 15, 2014, and interim periods within those years. Early adoption is permitted only for disposals (or classifications as held for sale) that have not been reported in financial statements previously issued or available for issuance. ASU 2014-08 is not expected to have a material impact on our consolidated financial position, results of operations, or cash flows.

Business_Description_and_Summa2

Business Description and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Revenues by Geographic Region	Revenue by geographical region is as follows:
		Year ended
		December 31,
		2014		2013
	United States	$	34,643,571	$	32,458,822
	Rest of World		688,241		584,592
		$	35,331,812	$	33,073,414
Schedule Of Accrued Stock Compensation	The following tables set forth by level, within the fair value hierarchy, our assets and liabilities as of the years ended December 31, 2014 and December 31, 2013, respectively, that are measured at fair value on a recurring basis:
	Accrued stock compensation
		As of		As of
		December 31,		December 31,
		2014		2013
	Level 1	$	-	$	211,212
	Level 2		-		-
	Level 3		-		-
Schedule of Assets and Liabilities Measured on Recurring Basis	The valuation technique used to measure fair value of the accrued stock compensation is based on quoted stock market prices.
	Warrant derivative liability
		As of		As of
		December 31,		December 31,
		2014		2013
	Level 1		-		-
	Level 2		-		-
	Level 3	$	1,320,371	$	1,594,628
Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The following is a reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the year ending December 31, 2014:
	Warrant derivative liability
	Balance at January 1, 2014	$	1,594,628
	Warrants issued with stock offering		1,461,796
	Gain recognized in earnings		-1,736,053
	Balance at December 31, 2014	$	1,320,371

Inventories_Tables

Inventories (Tables)	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consist of the following:
		December 31,		December 31,
		2014		2013
	Current inventories
	Raw materials	$	3,836,635	$	2,710,091
	Work in process		2,484,635		3,333,672
	Finished goods		5,163,458		5,775,813
			11,484,728		11,819,576
	Reserve for obsolescence		-1,926,080		-1,065,976
	Current inventories, total		9,558,648		10,753,600
	Non-current inventories
	Finished goods		2,860,248		3,341,411
	Reserve for obsolescence		-925,990		-1,221,459
	Non-current inventories, total		1,934,258		2,119,952
	Total inventories	$	11,492,906	$	12,873,552

Property_and_Equipment_Net_Tab

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment, Net	Property and equipment, net are as follows:
		December 31,		December 31,
		2014		2013
	Buildings	$	1,657,579	$	1,653,263
	Equipment		4,724,608		5,768,478
	Computer equipment		225,009		312,650
	Computer software		345,039		395,146
	Furniture and fixtures		153,834		170,118
	Leasehold improvements		2,380,617		1,808,461
	Vehicles		41,099		41,099
	Total cost		9,527,785		10,149,215
	Less: accumulated depreciation		-4,873,258		-4,968,659
		$	4,654,527	$	5,180,556

Intangible_Assets_Tables

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	The following table sets forth information regarding intangible assets:
		December 31,		December 31,
		2014		2013
	Intellectual Property
	Gross carrying value	$	1,036,580	$	891,034
	Accumulated amortization		-381,090		-304,069
	Net carrying value	$	655,490	$	586,965
	Aggregate amortization expense for the years ended December 31, 2014 and 2013, respectively:	$	77,022	$	75,668
Schedule of Estimated Amortization Expense for Intangible Assets	The following is a summary of estimated future amortization expense for intangible assets as of December 31, 2014:
	2015	$	90,055
	2016		58,639
	2017		58,639
	2018		58,639
	2019		55,105
	Thereafter		334,413
	Total	$	655,490

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consist of the following:
		December 31,		December 31,
		2014		2013
	Accrued stock compensation	$	-	$	211,212
	Wages/commissions payable		1,434,743		1,728,576
	Other accrued expenses		486,558		1,645,249
		$	1,921,301	$	3,585,037

Longterm_Debt_Tables

Long-term Debt (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Schedule of Calculation Buyout	The table below is for illustration purposes only and there can be no assurance that we will achieve the minimum revenue required by the financial covenants or that we will make all required payments on a timely basis.
	Calculation of ROS Buyout	Repurchase		Interest/		Estimated		Estimated		Net
		Price		Principal		Royalty on		Total		Buyout
				Payments		Minimum		Cumulative		Amount
						revenue		Payments
	Between August 24, 2014 and August 24, 2015	$	40,000,000	$	3,151,200	$	638,750	$	10,508,117	$	29,491,883
	Between August 24, 2015 and August 24, 2016	$	45,000,000	$	3,151,200	$	665,000	$	14,324,317	$	30,675,683
	Between August 24, 2016 and August 24, 2017	$	52,500,000	$	9,721,896	$	665,000	$	24,711,213	$	27,788,787
	After August 24, 2017	$	56,250,000	$	9,721,896	$	665,000	$	35,098,109	$	21,151,891
Schedule of Long-term Debt	Long-term debt consists of the following:
		December 31,		December 31,
		2014		2013
	Loan payable to ROS Acquisition Offshore, LIBOR plus 12.13% maturing August 2019	$	24,000,000	$	20,000,000
	Adjustment fee payable to ROS Acquisition Offshore, due in August 2019		700,000		700,000
	6.00% loan payable to Valley Bank of Belgrade, $10,746 monthly payments including interest, maturing December 24, 2030; secured by building		1,325,814		1,375,030
			26,025,814		22,075,030
	Less: current portion		-50,671		-47,727
	Debt discount		-5,104,813		-5,642,058
	Long-term debt	$	20,870,330	$	16,385,245
Schedule of Maturities of Long-term Debt	The following is a summary of maturities due on the debt as of December 31, 2014:
	2015	$	50,609
	2016		2,112,064
	2017		8,290,378
	2018		8,293,897
	2019		6,239,295
	2020 and thereafter		1,039,571
	Total	$	26,025,814
Schedule of Royalty Payments	The following is a summary of estimated future royalty payments as of December 31, 2014:
	2015	$	1,000,750
	2016		1,229,250
	2017		1,360,250
	2018		1,462,750
	2019		1,575,250
	Thereafter		5,626,325
	Total	$	12,254,575

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity	Stock option activity under the Plan, plus the Non-Plan Grants, was as follows:
		2014						2013
				Weighted		Weighted				Weighted		Weighted
				Average		Average Fair				Average		Average Fair
				Exercise		Value at Grant				Exercise		Value at Grant
		Shares		Price		Date		Shares		Price		Date
	Outstanding at January 1		758,328	$	14.9	$	8.6		526,653	$	20.2	$	10.3
	Granted		169,300		5.78		2.65		333,125		6.3		5.3
	Exercised		-6,666		10		0.04		-23,000		1		0.6
	Cancelled or expired		-225,626		11.38		6.07		-78,450		17.6		8.9
	Outstanding at December 31		695,336	$	11.09	$	5.35		758,328	$	14.9	$	8.6
	Exercisable at December 31		311,080	$	15.25	$	7.35		264,272	$	20.1	$	10.3
Schedule of Share-based Compensation, Restricted Stock Units Award Activity	The following table summarizes restricted stock award activity during the year ended December 31, 2014:
		Shares
	Outstanding at January 1, 2013		73,390
	Cancelled		-27,868
	Vested		-14,672
	Outstanding at January 1, 2014		30,850
	Awarded		39,312
	Cancelled		-30,850
	Vested		-
	Outstanding at December 31, 2014		39,312

Warrants_Tables

Warrants (Tables)	12 Months Ended
	Dec. 31, 2014
Warrants and Rights Note Disclosure [Abstract]
Schedule of Warrant Activity	The following table summarizes our warrant activities for the period ended December 31, 2014:
					Weighted
					Average
					Exercise
		Shares			Price
	Outstanding as of January 1, 2013		732,167		$	22
	Issued		435,222			7.2
	Expired		-79,569			20
	Outstanding at January 1, 2014		1,087,820		$	16.2
	Issued		571,500			7.12
	Expired		-4,000			20
	Outstanding at December 31, 2014		1,655,320			13.06
Schedule of Warrant Valuation Assumptions	The estimated fair value was derived using the lattice model with the following weighted-average assumptions:
		Year ended
		December 31,
		2014				2013
	Value of underlying common stock (per share)	$	3.03			$	5
	Risk free interest rate		0.8	%			0.89	%
	Expected term		5.00 years				5.56 years
	Dividend yield		0				0
	Volatility		75	%			65	%
Schedule of Warrants Activities Used In Derivative Liability	The following table summarizes our activities related to warrants accounted for as a derivative liability for the year ended December 31, 2014 and 2013:
		2014			2013
	Balance at January 1, 2014		600,192			164,971
	Derivative warrants issued		571,500			435,221
	Derivative warrants exercised		-			-
	Balance at December 31, 2014		1,171,692			600,192

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	Future minimum payments for the next five years and thereafter as of December 31, 2014, under these leases, are as follows:
	2015	$	334,317
	2016		269,400
	2017		269,400
	2018		269,400
	2019		269,400
	Thereafter		559,000
	Total	$	1,970,917

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Loss Before Provision For Income Taxes	The components of income (loss) before provision for income taxes consist of the following:
		Year Ended December 31,
		2014		2013
	United States	$	-10,507,869	$	-12,693,125
		$	-10,507,869	$	-12,693,125
Schedule of Components of Income Tax Expense (Benefit)	The components of the income tax provision are as follows:
		Year Ended December 31,
		2014		2013
	Current:
	Federal	$	-	$	-
	State		-		-
	Total current		-		-
	Deferred:
	Federal		-		-
	State		-		-
	Total deferred		-		-
		$	-	$	-
Schedule of Effective Income Tax Rate Reconciliation	The reconciliation of income tax attributable to operations computed at the U.S. Federal statutory income tax rate of 35% to income tax expense is as follows:
		Year Ended December 31,
		2014		2013
	Statutory Federal tax rate	$	-3,677,754	$	-4,442,594
	Valuation allowance		4,909,776		4,112,338
	State income taxes, net of Federal benefit		-368,826		-528,034
	Change in state income tax rate		277,076		574,964
	Provision to return adjustment		-505,423		-
	Change in Warrant Derivative Liability		-668,554		-342,666
	Stock issued in exchange for debt waiver		-		581,649
	Nondeductible meals, entertainment and other expense		33,705		44,343
		$	-	$	-
Schedule of Deferred Tax Assets and Liabilities	Deferred tax assets and liabilities are as follows:
		At December 31,
		2014		2013
	Deferred tax assets:
	Current deferred tax assets
	Accrued liability for vacation	$	102,643	$	85,599
	Bad debt reserve		536,440		512,941
	Charitable contributions carryforward		33,124		19,746
	Inventory reserve		1,098,333		895,760
	Reserve – assets held for sale		351,423		-
	Restricted stock compensation		-		82,640
	Total current deferred tax assets		2,121,963		1,596,686
	Valuation Allowance		-2,121,963		-1,596,686
	Net current deferred tax assets		-		-
	Noncurrent deferred tax assets
	Net operating loss carryovers		18,200,823		14,863,919
	Stock warrants		131,891		134,117
	Stock option compensation		1,594,460		1,307,998
	Goodwill amortization		82,212		90,868
	Debt discount and waiver amortization		1,076,926		455,916
	Depreciation		244,004		97,492
	Amortization		30,290		25,797
	Total noncurrent deferred tax assets		21,360,606		16,976,107
	Valuation allowance		-21,360,606		-16,976,107
	Net noncurrent deferred tax assets		-		-
	Net deferred tax assets	$	-	$	-

Supplemental_Disclosure_of_Cas1

Supplemental Disclosure of Cash Flow Information (Tables)	12 Months Ended
	Dec. 31, 2014
Supplemental Cash Flow Elements [Abstract]
Supplemental Disclosure of Cash Flow Information	Supplemental cash flow information is as follows:
		Twelve Months Ended
		December 31,
		2014		2013
	Supplemental disclosure of cash flow information
	Cash paid during the period for:
	Interest	$	3,192,854	$	2,681,459
	Non-cash activities:
	Settlement of SeaArk accounts receivable	$	-	$	1,829,647
	Inventory received in SeaArk settlement	$	-	$	409,838
	Write-off of SeaArk allowance for doubtful accounts	$	-	$	1,419,809
	Issuance of Warrants related to stock issuance	$	1,461,796	$	1,485,313
	Increase in long-term debt, ROS adjustment fee	$	-	$	700,000
	Issuance of shares, ROS adjustment fee	$	-	$	630,000
	Issuance of shares related to debt issuance	$	1,094,999	$	-
	Issuance of restricted stock to employees	$	136,977	$	-

Business_Description_and_Summa3

Business Description and Summary of Significant Accounting Policies (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Revenues	$35,331,812	$33,073,414
US [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Revenues	34,643,571	32,458,822
Rest Of World [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Revenues	$688,241	$584,592

Business_Description_and_Summa4

Business Description and Summary of Significant Accounting Policies (Details 1) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Accrued stock compensation	$0	$211,212
Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Accrued stock compensation	0	211,212
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Accrued stock compensation	0	0
Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Accrued stock compensation	$0	$0

Business_Description_and_Summa5

Business Description and Summary of Significant Accounting Policies (Details 2) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant derivative liability	$1,320,371	$1,594,628
Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant derivative liability	0	0
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant derivative liability	0	0
Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant derivative liability	$1,320,371	$1,594,628

Business_Description_and_Summa6

Business Description and Summary of Significant Accounting Policies (Details 3) (Warrant [Member], Derivative [Member], USD $)	12 Months Ended
	Dec. 31, 2014
Warrant [Member] | Derivative [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance at January 1, 2014	$1,594,628
Warrants issued with stock offering	1,461,796
Gain recognized in earnings	-1,736,053
Balance at December 31, 2014	$1,320,371

Business_Description_and_Summa7

Business Description and Summary of Significant Accounting Policies (Details Textual) (USD $)	0 Months Ended		1 Months Ended	0 Months Ended	3 Months Ended	12 Months Ended
	Aug. 06, 2014	Nov. 14, 2013	Nov. 25, 2013	Jun. 10, 2013	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Estimable useful lives						15 years
Advertising Expense						$34,970	$47,000
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount						2,350,656	1,846,148
Royalty Revenue Description						The Company also receives royalty revenue from third parties related to licensing agreements. The Company has royalty agreements with RyMed and Bard Access Systems. Revenue under these agreements represented less than 0.5% of total revenue for the years ended December 31, 2014 and 2013.
Proceeds From Issuance Or Sale Of Equity Gross	6,500,000
Stock Issued During Period, Shares, New Issues			150,000	851,000	150,000
Shares Issued, Price Per Share				$5.70
Class of Warrant or Right, Exercise Price of Warrants or Rights						$13.06	$16.20	$22
Proceeds from Issuance or Sale of Equity, Total	$5,900,000	$10,500,000		$4,450,000
Common Stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock Issued During Period, Shares, New Issues	1,143,000					1,143,000	850,877
Shares Issued, Price Per Share	$5.70
August 2014 Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	571,500
Class of Warrant or Right, Exercise Price of Warrants or Rights	$7.12
Class Of Warrant Or Right Term	5 years
Sales Revenue, Net [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Concentration Risk, Percentage						1.40%	1.20%
Building [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Property, Plant and Equipment, Useful Life						30 years
Computers and Equipment [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Property, Plant and Equipment, Useful Life						3 years
Computers and Equipment [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Property, Plant and Equipment, Useful Life						7 years
Geographic Concentration Risk [Member] | Sales Revenue, Net [Member] | US [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Concentration Risk, Percentage						98.00%	98.00%

Equity_Details_Textual

Equity (Details Textual) (USD $)	0 Months Ended		1 Months Ended	0 Months Ended	3 Months Ended	12 Months Ended	0 Months Ended	12 Months Ended
	Aug. 06, 2014	Nov. 14, 2013	Nov. 25, 2013	Jun. 10, 2013	Mar. 31, 2014	Dec. 31, 2014	Mar. 06, 2014	Dec. 31, 2013	Dec. 31, 2012
Schedule of Equity Method Investments [Line Items]
Stock issued (in shares)			150,000	851,000	150,000
Stock Issued During Period, Percentage Of Discount Based On 4 June 2013 Closing Price				10.00%
Warrants Issued In Offering, Right To Acquire Common Shares Per Warrant				0.5
Warrants Issued In Offering, Exercise Price				$7.20
Warrant Issued In Offering, Percentage Of Premium Based On 4 June 2013 Closing Price				15.00%
Proceeds from Issuance or Sale of Equity, Total	$5,900,000	$10,500,000		$4,450,000
Payments of Stock Issuance Costs				400,000
Proceeds From Issuance Or Sale Of Equity Gross	6,500,000
Shares Issued, Price Per Share				$5.70
Proceeds from Lines of Credit						4,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights						$13.06		16.2	$22
Ros Acquisition Offshore [Member]
Schedule of Equity Method Investments [Line Items]
Proceeds from Lines of Credit					$4,000,000		$4,000,000
Common Stock [Member]
Schedule of Equity Method Investments [Line Items]
Stock issued (in shares)	1,143,000					1,143,000		850,877
Shares Issued, Price Per Share	$5.70
August 2014 Warrants [Member]
Schedule of Equity Method Investments [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	571,500
Class of Warrant or Right, Exercise Price of Warrants or Rights	$7.12

Inventories_Details

Inventories (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current inventories
Raw materials	$3,836,635	$2,710,091
Work in process	2,484,635	3,333,672
Finished goods	5,163,458	5,775,813
Inventory, Gross	11,484,728	11,819,576
Reserve for obsolescence	-1,926,080	-1,065,976
Current inventories, total	9,558,648	10,753,600
Non-current inventories
Finished goods	2,860,248	3,341,411
Reserve for obsolescence	-925,990	-1,221,459
Non-current inventories, total	1,934,258	2,119,952
Total inventories	$11,492,906	$12,873,552

Impairment_of_Assets_Details_T

Impairment of Assets (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Property, Plant and Equipment	$80,042
Disposal Group, Including Discontinued Operation, Inventory	832,507
Disposal Group, Including Discontinued Operation, Assets	0
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent	912,549
Goodwill, Impairment Loss		728,618
Prepaid Expenses and Other Current Assets [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Assets	$912,549
Gross Profit [Member] | Maximum [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Concentration Risk, Percentage	1.00%	1.00%
Sales Revenue, Net [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Concentration Risk, Percentage	1.40%	1.20%

Property_and_Equipment_Net_Det

Property and Equipment, Net (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Total cost	$9,527,785	$10,149,215
Less: accumulated depreciation	-4,873,258	-4,968,659
Property and equipment, net	4,654,527	5,180,556
Building [Member]
Property, Plant and Equipment [Line Items]
Total cost	1,657,579	1,653,263
Equipment [Member]
Property, Plant and Equipment [Line Items]
Total cost	4,724,608	5,768,478
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Total cost	225,009	312,650
Computer software[Member]
Property, Plant and Equipment [Line Items]
Total cost	345,039	395,146
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Total cost	153,834	170,118
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total cost	2,380,617	1,808,461
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Total cost	$41,099	$41,099

Property_and_Equipment_Net_Det1

Property and Equipment, Net (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Capital Leased Assets, Gross	$443,060	$549,604
Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation	191,174	159,722
Cost of Property Repairs and Maintenance	293,707	244,398
Depreciation	$570,726	$677,856

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Intellectual Property
Gross carrying value	$1,036,580	$891,034
Accumulated amortization	-381,090	-304,069
Net carrying value	655,490	586,965
Aggregate amortization expense	$77,022	$75,668

Intangible_Assets_Details_1

Intangible Assets (Details 1) (USD $)	Dec. 31, 2014
Estimated amortization expense:
2015	$90,055
2016	58,639
2017	58,639
2018	58,639
2019	55,105
Thereafter	334,413
Total	$655,490

Accrued_Liabilities_Details

Accrued Liabilities (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Accrued Liabilities [Line Items]
Accrued stock compensation	$0	$211,212
Wages/commissions payable	1,434,743	1,728,576
Other accrued expenses	486,558	1,645,249
Accrued Liabilities Current	$1,921,301	$3,585,037

Longterm_Debt_Details

Long-term Debt (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Between August 24, 2014 and August 24, 2015 [Member]
Calculation Of Buyout [Line Items]
Repurchase Price	$40,000,000
Interest/Principal Payments	3,151,200
Estimated Royalty On Minimum Revenue	638,750
Estimated Cumulative Payments	10,508,117
Net Buyout Amount	29,491,883
Between August 24, 2015 and August 24, 2016 [Member]
Calculation Of Buyout [Line Items]
Repurchase Price	45,000,000
Interest/Principal Payments	3,151,200
Estimated Royalty On Minimum Revenue	665,000
Estimated Cumulative Payments	14,324,317
Net Buyout Amount	30,675,683
Between August 24, 2016 and August 24, 2017 [Member]
Calculation Of Buyout [Line Items]
Repurchase Price	52,500,000
Interest/Principal Payments	9,721,896
Estimated Royalty On Minimum Revenue	665,000
Estimated Cumulative Payments	24,711,213
Net Buyout Amount	27,788,787
After August 24, 2017 [Member]
Calculation Of Buyout [Line Items]
Repurchase Price	56,250,000
Interest/Principal Payments	9,721,896
Estimated Royalty On Minimum Revenue	665,000
Estimated Cumulative Payments	35,098,109
Net Buyout Amount	$21,151,891

Longterm_Debt_Details_1

Long-term Debt (Details 1) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Loan Payable	$26,025,814	$22,075,030
Less: current portion	-50,671	-47,727
Debt discount	-5,104,813	-5,642,058
Long-term debt	20,870,330	16,385,245
Ros Acquisition Offshore [Member]
Debt Instrument [Line Items]
Loan Payable	24,000,000	20,000,000
Adjustment fee payable to ROS Acquisition Offshore August 2019	700,000	700,000
Valley Bank Of Belgrade [Member]
Debt Instrument [Line Items]
Loan Payable	$1,325,814	$1,375,030

Longterm_Debt_Details_2

Long-term Debt (Details 2) (USD $)	Dec. 31, 2014
Schedule of maturities due on debt [Line Items]
2015	$50,609
2016	2,112,064
2017	8,290,378
2018	8,293,897
2019	6,239,295
2020 and thereafter	1,039,571
Total	$26,025,814

Longterm_Debt_Details_3

Long-term Debt (Details 3) (USD $)	Dec. 31, 2014
Estimated future royalty payments [Line Items]
2015	$1,000,750
2016	1,229,250
2017	1,360,250
2018	1,462,750
2019	1,575,250
Thereafter	5,626,325
Total	$12,254,575

Longterm_Debt_Details_Textual

Long-term Debt (Details Textual) (USD $)	0 Months Ended		12 Months Ended	1 Months Ended	0 Months Ended		3 Months Ended
	Aug. 12, 2013	16-May-13	Dec. 31, 2014	Aug. 24, 2012	Mar. 06, 2014	Nov. 14, 2013	Mar. 31, 2014
Debt Instrument [Line Items]
Royalty liability related to financing			$12,300,000
Line of Credit Facility Additional Fee Percentage	2.00%	1.50%
Line of Credit Facility Prior Additional Fee Percentage	1.50%
Waivers And Modifications Fee Percentage			3.50%
Proceeds from Lines of Credit			4,000,000
Royalty Expense			7,361,966
Midcap and Silicon Valley Bank [Member] | Prepayment Penalties [Member]
Debt Instrument [Line Items]
Proceeds from Other Debt				10,000,000
Valley Bank Of Belgrade [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Effective Percentage			6.00%
Debt Instrument, Periodic Payment			10,746
Debt Instrument, Maturity Date, Description			24-Dec-30
Ros Acquisition Offshore [Member]
Debt Instrument [Line Items]
Debt Instrument, Unused Borrowing Capacity, Amount				5,000,000
Line of Credit Facility, Description			LIBOR plus 12.13% maturing August 2019		LIBOR plus 12.13%, subject to a LIBOR floor rate of 1.0%.
Royalty Expenses Description					royalty of 1.75% on the first $45,000,000 of net sales, plus 1.0% of net sales in excess of $45,000,000 for ten years
Amendment To Credit Agreement, Minimum Liquidity Requirement Amount		1,500,000
Minimum Liquidity Requirement Amount		750,000
Debt Conversion, Converted Instrument, Shares Issued					150,000	150,000
Proceeds from Lines of Credit					4,000,000		4,000,000
Line of Credit Facility, Current Borrowing Capacity				$20,000,000
Repurchase Option [Member]
Debt Instrument [Line Items]
Royalty Expenses Description					principal, interest and royalty payments, is as follows: (a) $40,000,000 if we exercise the repurchase option between August 24, 2014 and August 24, 2015; (b) $45,000,000 if we exercise the purchase option between August 24, 2015 and August 24, 2016; (c) $52,500,000 if we exercise the repurchase option between August 24, 2016 and August 24, 2017; and (d) $56,250,000 if we exercise the repurchase option after August 24, 2017.
Line of Credit Facility Additional Fee Percentage	3.50%

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (Stock Option, USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Stock Option
Schedule of activity under stock option plans [Line Items]
Outstanding at January 1, Shares	758,328	526,653
Granted, Shares	169,300	333,125
Exercised, Shares	-6,666	-23,000
Cancelled or expired, Shares	-225,626	-78,450
Outstanding at December 31, Shares	695,336	758,328
Exercisable at December 31, Shares	311,080	264,272
Outstanding at January 1, Weighted Average Exercise Price	$14.90	$20.20
Granted, Weighted Average Exercise Price	$5.78	$6.30
Exercised, Weighted Average Exercise Price	$10	$1
Cancelled or expired, Weighted Average Exercise Price	$11.38	$17.60
Outstanding at December 31, Weighted Average Exercise Price	$11.09	$14.90
Exercisable at December 31, Weighted Average Exercise Price	$15.25	$20.10
Outstanding at January 1, Weighted Average Fair Value At Grant Date	$8.60	$10.30
Granted, Weighted Average Fair Value At Grant Date	$2.65	$5.30
Exercised, Weighted Average Fair Value At Grant Date	$0.04	$0.60
Cancelled or expired, Weighted Average Fair Value At Grant Date	$6.07	$8.90
Outstanding at December 31, Weighted Average Fair Value At Grant Date	$5.35	$8.60
Exercisable at December 31, Weighted Average Fair Value At Grant Date	$7.35	$10.30

StockBased_Compensation_Detail1

Stock-Based Compensation (Details 1)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Restricted stock award activity [Line Items]
Outstanding Shares	30,850	73,390
Awarded, Shares	39,312
Cancelled, Shares	-30,850	-27,868
Vested, Shares	0	-14,672
Outstanding Shares	39,312	30,850

StockBased_Compensation_Detail2

Stock-Based Compensation (Details Textual) (USD $)	12 Months Ended		1 Months Ended		0 Months Ended	1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Jul. 31, 2014	Aug. 31, 2013	Nov. 10, 2014	24-May-13
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Shares authorized under the Plan	900,000
Aggregate intrinsic value of options outstanding	107,700
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.92%	1.16%
Allocated Share-based Compensation Expense	$935,316	$975,905
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	5 years 4 months 24 days	6 years 2 months 12 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	57.00%	66.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	39,312
Forfeiture Rate	20.00%
Employee Stock Option [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	23,345
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	23,345
Share Based Compensation Arrangements By Share Based Payment Award Options Unvested Options	384,256
Granted, Weighted Average Fair Value At Grant Date	$12.54
Allocated Share-based Compensation Expense	795,221
Options granted			55,000
Employee Stock Option [Member] | Chief Executive Officer [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options granted				200,000
Restricted Stock [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Allocated Share-based Compensation Expense	135,075	-5,117
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period					39,312	33,500
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options					$160,000	$227,800
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Issue Price On Grand Date					$4.07	$6.80
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights					vest on July 1, 2015

Warrants_Details

Warrants (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
warrant activity [Line Items]
Outstanding	1,087,820	732,167
Issued, Shares	571,500	435,222
Expired, Shares	-4,000	-79,569
Outstanding	1,655,320	1,087,820
Outstanding Weighted Average Exercise Price	$16.20	$22
Issued, Weighted Average Exercise Price	$7.12	$7.20
Expired, Weighted Average Exercise Price	$20	$20
Outstanding Weighted Average Exercise Price	$13.06	$16.20

Warrants_Details_1

Warrants (Details 1) (Warrant [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Warrant [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Value of underlying common stock (per share)	$3.03	$5
Risk free interest rate	0.80%	0.89%
Expected term	5 years	5 years 6 months 22 days
Dividend yield	0.00%	0.00%
Volatility	75.00%	65.00%

Warrants_Details_2

Warrants (Details 2)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Class of Warrant or Right [Line Items]
Outstanding	1,087,820	732,167
Derivative warrants issued	571,500	435,222
Outstanding	1,655,320	1,087,820
Warrant [Member]
Class of Warrant or Right [Line Items]
Outstanding	600,192	164,971
Derivative warrants issued	571,500	435,221
Derivative warrants exercised	0	0
Outstanding	1,171,692	600,192

Warrants_Details_Textual

Warrants (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014
Class of Warrant or Right [Line Items]
Unrealized Gain On Warranty Derivative Liability	$1,736,053

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	Dec. 31, 2014
Schedule of future minimum payments by operating lease [Line Items]
2015	$334,317
2016	269,400
2017	269,400
2018	269,400
2019	269,400
Thereafter	559,000
Total	$1,970,917

Commitments_and_Contingencies_2

Commitments and Contingencies (Details Textual) (USD $)	1 Months Ended	0 Months Ended	12 Months Ended		1 Months Ended	0 Months Ended
	Nov. 19, 2013	13-May-13	Dec. 31, 2014	Dec. 31, 2013	Mar. 17, 2014	Jul. 09, 2014	Jul. 14, 2014
Schedule of commitment and contingencies [Line Items]
Operating Leases, Rent Expense, Net			$365,000	$283,000
Market Exchange Notification Description	On November 19, 2013, we received another letter from the NYSE MKT notifying us that we are not in compliance with Section 1003(a)(i) of the Company Guide with stockholders equity of less than $2,000,000 as of September 30, 2013 and net losses in two of three of our most recent fiscal years, and we submitted an amended plan to regain compliance.	On May 13, 2013, we received a deficiency notice from the NYSE MKT notifying us that we are not in compliance with Section 1003(a)(iii) of the Company Guide with stockholders equity of less than $6,000,000 and net losses in five of our most recent fiscal years and Section 1003(a)(ii) with stockholders equity of less than $4,000,000 and net losses in three of our four most recent fiscal years.	On May 13, 2013, we received a deficiency notice from the NYSE MKT notifying us that we are not in compliance with Section 1003(a)(iii) of the Company Guide with stockholders’ equity of less than $6,000,000 and net losses in five of our most recent fiscal years and Section 1003(a)(ii) with stockholders’ equity of less than $4,000,000 and net losses in three of our four most recent fiscal years. On June 12, 2013 we submitted a plan to regain compliance with the continued listing requirements, and on June 21, 2013 the NYSE MKT informed us of the acceptance of our plan and gave us an extension until November 13, 2014 to regain compliance with the continued listing standards. On November 19, 2013, we received another letter from the NYSE MKT notifying us that we are not in compliance with Section 1003(a)(i) of the Company Guide with stockholders’ equity of less than $2,000,000 as of September 30, 2013 and net losses in two of three of our most recent fiscal years, and we submitted an amended plan to regain compliance. On November 14, 2014, we received a letter notifying us that the staff of NYSE Regulation, Inc. (the “Staff”) determined to commence proceedings to delist our common stock from the NYSE MKT because we did not cure our non-compliance with Sections 1003(a)(i), (ii) and (iii) of the NYSE MKT Company Guide by the end of the maximum 18 month compliance period, which expired on November 13, 2014. We appealed the Staff’s delisting determination and attended a hearing on January 21, 2015. On January 26, 2015, following our January 21, 2015 hearing with a Listing Qualifications Panel (the “Panel”) of the NYSE MKT LLC’s Committee on Securities (the “Committee”), we received a letter notifying us that the Panel affirmed the determination of the Staff to delist our common stock. We have requested a full Committee review of the Panel’s decision. If our common stock is delisted from the NYSE MKT, our stock price might be negatively affected, some shareholders may sell their shares, and we may not be able to attract institutional investors in future financing transactions. There can be no assurance that our common stock will remain listed on the NYSE MKT
Renewal term			10 years
Minimum [Member]
Schedule of commitment and contingencies [Line Items]
Lease Expiration Date			31-Dec-19
Robert Taggart V Guy Cook Bacterin International Inc [Member]
Schedule of commitment and contingencies [Line Items]
Loss Contingency, Damages Sought, Value					5,000,000
Middle bury Securities Llc V Bacterin International Inc [Member] | Litigation Fee [Member]
Schedule of commitment and contingencies [Line Items]
Loss Contingency, Damages Sought, Value						80,000
Middle bury Securities Llc V Bacterin International Inc [Member] | Litigation Warrants [Member]
Schedule of commitment and contingencies [Line Items]
Loss Contingency, Damages Sought, Value						80,000
Rodman And Renshaw Llc Debtor [Member]
Schedule of commitment and contingencies [Line Items]
Loss Contingency, Damages Sought, Value							$150,000

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Line Items]
Net Income	($10,507,869)	($12,693,125)
Domestic Tax Authority [Member]
Income Tax Disclosure [Line Items]
Net Income	($10,507,869)	($12,693,125)

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Current:
Federal	$0	$0
State	0	0
Total current	0	0
Deferred:
Federal	0	0
State	0	0
Total deferred	0	0
Total Income Tax	$0	$0

Income_Taxes_Details_2

Income Taxes (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Line Items]
Statutory Federal tax rate	($3,677,754)	($4,442,594)
Valuation allowance	4,909,776	4,112,338
State income taxes, net of Federal benefit	-368,826	-528,034
Change in state income tax rate	277,076	574,964
Provision to return adjustment	-505,423	0
Change in Warrant Derivative Liability	-668,554	-342,666
Stock issued in exchange for debt waiver	0	581,649
Nondeductible meals, entertainment and other expense	33,705	44,343
Total Income Tax Expense\Benefit	$0	$0

Income_Taxes_Details_3

Income Taxes (Details 3) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current deferred tax assets
Accrued liability for vacation	$102,643	$85,599
Bad debt reserve	536,440	512,941
Charitable contributions carryforward	33,124	19,746
Inventory reserve	1,098,333	895,760
Reserve - assets held for sale	351,423	0
Restricted stock compensation	0	82,640
Total current deferred tax assets	2,121,963	1,596,686
Valuation Allowance	-2,121,963	-1,596,686
Net current deferred tax assets	0	0
Noncurrent deferred tax assets
Net operating loss carryovers	18,200,823	14,863,919
Stock warrants	131,891	134,117
Stock option compensation	1,594,460	1,307,998
Goodwill amortization	82,212	90,868
Debt discount and waiver amortization	1,076,926	455,916
Depreciation	244,004	97,492
Amortization	30,290	25,797
Total noncurrent deferred tax assets	21,360,606	16,976,107
Valuation allowance	-21,360,606	-16,976,107
Net noncurrent deferred tax assets	0	0
Net deferred tax assets	$0	$0

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Line Items]
Valuation Allowance, Deferred Tax Asset, Change in Amount	$4,909,776	$4,112,338
Operating Loss Carryforwards	$47,262,588	$37,976,891
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	35.00%
Operating Loss Carryforward Expiration Dates1	Federal net operating loss carryovers expire at various dates between 2025 and 2034, while state net operating loss carryovers expire between 2025 and 2034
Operating Loss Carryforwards, Limitations on Use	Events which cause limitations in the amount of net operating losses that the Company may utilize in any one year include, but are not limited to, a cumulative ownership change of more than 50%, as defined, over a three year period.

Employee_Benefit_Plans_Details

Employee Benefit Plans (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014
Employee Benefit Plan [Line Items]
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	2.00%
Minimum [Member]
Employee Benefit Plan [Line Items]
Defined Benefit Plan, Contributions by Plan Participants	17,500

Supplemental_Disclosure_of_Cas2

Supplemental Disclosure of Cash Flow Information (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash paid during the period for:
Interest	$3,192,854	$2,681,459
Non-cash activities:
Settlement of SeaArk accounts receivable	0	1,829,647
Inventory received in SeaArk settlement	0	409,838
Write-off of SeaArk allowance for doubtful accounts	0	1,419,809
Issuance of Warrants related to stock issuance	1,461,796	1,485,313
Increase in long-term debt, ROS adjustment fee	0	700,000
Issuance of shares, ROS adjustment fee	0	630,000
Issuance of shares related to debt issuance	1,094,999	0
Issuance of restricted stock to employees	$136,977	$0

Related_Party_Transactions_Det

Related Party Transactions (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Director [Member]
Related Party Transaction [Line Items]
Amount of related party transaction	$5,000
Chief Operating Officer [Member]
Related Party Transaction [Line Items]
Amount of related party transaction	5,000
American Donor Services [Member]
Related Party Transaction [Line Items]
Amount of related party transaction	2,406,926	2,055,523
West Coast Tissue Services [Member]
Related Party Transaction [Line Items]
Amount of related party transaction	98,600	840,100
International Biologics, LLC [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Due from (to) Related Party, Total	33,468
Lacuna Hedge Fund LLLP [Member]
Related Party Transaction [Line Items]
Recovery of Direct Costs	$350,000

Subsequent_Events_Details_Text

Subsequent Events (Details Textual) (Subsequent Event [Member], USD $)	0 Months Ended
	Mar. 16, 2015
Initial Purchase Shares [Member]
Subsequent Event [Line Items]
Minimum Number Of Shares Agreed To Buy Under Agreement	207,182
Minimum Number Of Shares Value Agreed To Buy Under Agreement	$750,000
Aspire Capital [Member]
Subsequent Event [Line Items]
Number Shares Committed To Purchase The Common Stock Value	10,000,000
Subsequent Event, Description	Aspire Capital is committed to purchase up to an aggregate of $10.0 million of shares of our common stock over the 24-month term after a registration statement is declared effective by the U.S. Securities and Exchange Commission (“SEC”) relating to the transaction
Number Shares Committed To Purchase The Common Stock Remaining Value	$9,250,000
Other Commitments, Description	purchase up to 50,000 shares of our common stock, per trading day, provided that the aggregate price of each such purchase shall not exceed $500,000 per trading day at a per share price
Right To Purchase The Amount Of Common Stock Description	right to present Aspire Capital with volume-weighted average price purchase notices directing Aspire Capital to purchase an amount of stock equal to up to 30% of the aggregate shares of our common stock traded on the NYSE MTK on the next trading day subject to the terms, conditions and limitations in the Purchase Agreement.
Aspire Capital [Member] | Commitment Shares [Member]
Subsequent Event [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance	154,189